

Uric Acid and Diabetic Retinopathy: A Systematic Review and Meta-Analysis

Yicong Guo, Siyue Liu and Huilan Xu*

Department of Social Medicine and Health Management, Xiangya School of Public Health, Central South University, Changsha, China

Background: The relationship between uric acid (UA) and diabetic retinopathy (DR) remains ambiguous, and the results of current studies on the UA levels in patients with DR are conflicting. A meta-analysis was performed to provide a better understanding of the relationship between UA levels and DR.

OPEN ACCESS

Edited by:

Michele Lanza, University of Campania Luigi Vanvitelli, Italy

Reviewed by:

Taiji Nagaoka, Nihon University, Japan Yan Zhang, Tianjin Medical University Eye Hospital, China Qianyi Lu, The First Affiliated Hospital of Soochow University, China

> *Correspondence: Huilan Xu xhl_csu@163.com

Specialty section:

This article was submitted to Clinical Diabetes, a section of the journal Frontiers in Public Health

Received: 29 March 2022 Accepted: 09 May 2022 Published: 31 May 2022

Citation:

Guo Y, Liu S and Xu H (2022) Uric Acid and Diabetic Retinopathy: A Systematic Review and Meta-Analysis. Front. Public Health 10:906760. doi: 10.3389/fpubh.2022.906760 **Methods:** PubMed, Web of Science, Embase, and the Cochrane Library databases were searched until December 11, 2021 to identify eligible studies, that compared the UA levels of the case group (patients with DR) and control group (controls with diabetes and healthy participants). The weighted mean difference (WMD) with a 95% confidence interval (CI) was used to evaluate the difference in UA levels between the case and control groups.

Results: Twenty-one studies involving 4,340 patients with DR and 8,595 controls (8,029 controls with diabetes and 566 healthy participants) were included in this meta-analysis. We found that patients with DR had significantly higher UA levels than those in the controls with diabetes (WMD = 36.28; 95% CI: 15.68, 56.89; P < 0.001) and healthy participants (WMD = 70.80; 95% CI: 19.85, 121.75; P = 0.006). There was an obvious heterogeneity among the 21 studies ($l^2 = 97\%$, P < 0.001). Subgroup analyses of different phases of DR showed that UA levels were significantly increased in participants with proliferative diabetic retinopathy (PDR) (WMD = 46.57; 95% CI: 28.51, 64.63; P < 0.001) than in controls with diabetes; however, the difference is not statistically significant when comparing UA levels in patients with non-proliferative diabetic retinopathy (NPDR) and controls with diabetes (WMD = 22.50; 95% CI: -6.07, 51.08; P = 0.120). In addition, UA levels were higher in participants with a body mass index (BMI) \geq 25.0 kg/m² and over 15 years of diabetes. Univariate meta-regression analysis revealed that BMI (P = 0.007, Adj $R^2 = 40.12\%$) and fasting blood glucose (FBG) (P = 0.040, Adj $R^2 = 29.72\%$) contributed to between-study heterogeneity.

Conclusions: In conclusion, our study provides evidence that UA levels are higher in patients with DR than those in the controls, but this difference is not statistically significant in the early phases. UA might be a potential biomarker for identifying disease severity in patients with DR, rather than predicting the onset of DR among patients with diabetes.

1

However, more prospective and high-quality clinical evidence is required to confirm these present findings.

Systematic Review Registration: display record.php?RecordID=297708. https://www.crd.york.ac.uk/PROSPERO/

Keywords: uric acid, diabetic retinopathy, systematic review, meta-analysis, non-proliferative diabetic retinopathy, proliferative diabetic retinopathy

INTRODUCTION

According to the International Diabetes Federation (IDF) estimates of the global prevalence of diabetes mellitus (DM), 700 million (10.9%) people will have diabetes by 2045, representing a 51% increase compared with that in 2019 (1). With the increasing number of people with diabetes, it is foreseeable that the prevalence of diabetic retinopathy (DR) is also expected to increase. DR is a common microvascular complication of diabetes affecting more than 30% of patients with diabetes worldwide and is one of the leading causes of acquired blindness globally in the working-age adult population (2-4). DR is divided into two progressive phases, non-proliferative (earlier) and proliferative (late), and eventually deteriorates into visionthreatening DR (VTDR) (5). The pathogenesis of DR is known as a complex interplay between neuroglial and vascular damage that results from hyperglycemia-induced metabolic oxidative stress, and improving microcirculation of the retina was proven to be effective in preventing the early development of DR (6-9). In addition, previous studies have found that DR may be associated with inflammation and dysregulation of various inflammatory mediators (10-12).

Uric acid (UA) is the final product of purine metabolism and is typically considered the predominant predictor of gout. A UA concentration of 6 mg/dL is recommended as the threshold for the definition of hyperuricemia and as the minimum uricemia target for UA-lowering therapy in patients with gout (13). In addition to being closely linked to gout, increased UA levels have been shown to be associated with the risk of diabetes and some of its complications, such as diabetic peripheral neuropathy and diabetic nephropathy (14-16). Similarly, UA is likely to contribute to DR occurrence. For example, UA has been demonstrated to promote an inflammatory response to release inflammatory factors such as tumor necrosis factor-a (TNF- α), interleukin-6 (IL-6), and C-reactive protein (CRP) (17), and a recent meta-analysis showed that IL-6 was associated with the incidence of DR (18). However, the relationship between UA levels and DR remains ambiguous, and the results of current studies on UA levels in patients with DR are conflicting. Some studies have reported increased UA levels in patients with DR compared with patients with diabetes without DR (19-21), but the results of other studies were different or even opposite (22-25).

No meta-analytical data provided the overall information on this issue. Thus, to obtain a more precise assessment of the association between DR and serum and plasma UA levels and explore the possibility of UA as a predictor for DR in patients with diabetes, we conducted a systematic review and meta-analysis to summarize the current evidence.

METHODS

This systematic review and meta-analysis followed the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines (26). The PRISMA checklist for reporting the meta-analysis results is shown in **Supplementary Table 1**. The study protocol was registered in the PROSPERO International Prospective Register of Systematic Reviews (CRD42022297708).

Literature Search

We performed a comprehensive search of PubMed, Web of Science, Embase, and the Cochrane Library databases up to December 11, 2021, to acquire original articles. A combination of keywords and mesh terms was used as a search strategy: ("uric acid" OR "urate" OR "hyperuricemia" OR "serum uric acid") AND ("diabetic retinopathy" OR "diabetic complication" OR "microvascular complication" OR "DR"). The terms were appropriately adjusted for each database. We also screened the references of relevant studies and reviewed articles to identify additional published and unpublished records.

Inclusion and Exclusion Criteria

Our meta-analysis included all studies meeting the following explicit criteria: (1) studies were designed as a comparative study, completely involving a case group (patients with diabetes with DR) and control group (patients with diabetes without DR or participants without diabetes); (2) the concentrations of UA (mean and standard deviation) and the number of individuals in each group were available; (3) studies in which UA levels were measured in blood specimens (plasma, serum, or whole blood); and (4) studies were published or written in English.

The exclusion criteria were as follows: (1) case reports, abstracts, and reviews (including systematic reviews and metaanalyses); (2) study protocols, letters, comments, and conference abstracts; (3) experimental or animal studies; and (4) duplicate studies retrieved from various databases.

Data Extraction and Quality Assessment

For each eligible study, two authors (GY-C and LS-Y) independently extracted the following data: (1) first author's last name, publication year, region of study, the grouping of each study, and sample size; (2) demographic characteristics of participants, including ages, percentage of male participants, body mass index (BMI), types of diabetes, and duration of



diabetes; (3) laboratory test results in participants with diabetes such as fasting blood glucose (FBG), glycated hemoglobin A_{1c} (Hb A_{1c}), total cholesterol (TC), and low-density lipoprotein (LDL); (4) concentrations of UA (mean and standard deviation), and all of the units were converted into μ mol/L (1 mg/dL = 59.48

 $\mu mol/L);$ and (5) detecting methods and source of specimen for UA.

The quality of the included studies was assessed using the Newcastle-Ottawa Scale (NOS) for non-randomized studies. NOS is a rating scale in which points are awarded to studies based on selection, comparability, and exposure or outcome, where each study score ranges from 0 to 9 points (27). A study with a total quality score of more than 7 points was considered a high-quality study. Two researchers (GY-C and LS-Y) independently rated the study quality, and differences in ratings between reviewers were resolved by discussion.

Statistical Analysis

The fixed-effects (or random-effects) inverse-variance model (for continuous data) with the DerSimonian-Laird estimate of tau² was used to pool mean differences (MDs) from all included studies, and the weighted mean difference (WMD) with a 95% confidence interval (CI) was used to evaluate the difference in UA levels between the case and control groups. We generated a forest plot of the differences in UA levels between patients with DR and controls (controls with diabetes and healthy participants were separately compared). Heterogeneity was evaluated using Cochran's Q-statistic test and I-squared (I^2) . A value of I^2 of 0–25% represents insignificant heterogeneity, >25% but <50% represents low heterogeneity, >50% but <75% represents moderate heterogeneity, and >75% represents high heterogeneity (46, 47). The P-value of the Q-test <0.10 was considered statistically significant. If I^2 > 50% and P < 0.10, the random-effects model was used; otherwise, the fixed-effects model was applied (48). Subgroup analysis grouped by DR phases [non-proliferative diabetic retinopathy (NPDR) vs. controls with diabetes; proliferative diabetic retinopathy (PDR) vs. controls with diabetes; and PDR vs. NPDR], region (Asia and others), diabetes type (type 1, type 2, and both), duration of diabetes (<15 and >15 years), BMI (≤ 25 and > 25 kg/m²), FBG (≤ 150 and > 150 mg/dL), HbA1c (≤8.0% and >8.0%), LDL (≤120 and >120 mg/dL), specimen types (plasma and serum), and quality score (<7 and \geq 7) was performed to investigate the differences in studies or participants with different characteristics and explore the origin of heterogeneity. The UA concentrations in patients with DR were stratified (quartiles 1-4: 285.4-307.1; 307.1-333; 333-378.15; and 378.15-505.6 µmol/L) to explore a linear doseresponse correlation of the pooled results in patients with DR with different ranges of UA levels. When heterogeneity was high, a univariate meta-regression analysis was performed to identify potential confounding factors and explore the sources of heterogeneity. A sensitivity analysis was performed to evaluate the effect of a particular study on the overall results by omitting one study and combining the remainders in each turn. Egger's (49) and Begg's tests (50) were used to assess potential publication bias, and a visualized funnel plot was performed as a complement.

All statistical analyses were performed using RevMan 5.4 software (The Cochrane Collaboration, Copenhagen, Denmark) and Stata v16.0 (Stata Corp LP, College Station, TX, USA). A two-sided P < 0.05 was considered statistically significant except for the Cochran *Q*-test. In our study, all analyses were based on previously published research; therefore, no ethical approval or patient consent was required.

RESULTS

Search Results and Study Characteristics

Our search yielded 1,986 potentially relevant articles in electronic databases: 642 from PubMed, 940 from Embase, 386 from Web of Science, and 18 from the Cochrane Library. After excluding duplicate studies, 1,662 articles were retained. Of the 1,662 studies initially identified, 1,520 were excluded because they failed to meet the inclusion criteria based on title and abstract review. The full texts of the remaining 142 articles were reviewed for eligibility, and 121 articles were excluded for various reasons, such as not being retrieved, irrelevant studies, incomplete data, other outcomes, and a review article or conference abstract. We finally selected a total of 21 qualified articles (20, 22, 23, 28-45) involving 4,340 patients with DR and 8,595 controls (containing 8,029 controls with diabetes and 566 healthy participants) in this meta-analysis. A flowchart of the literature search process is shown in Figure 1.

Table 1 presents the characteristics of the 21 eligible studies, including the first author's last name, publication year, region, diabetes type, specimen type, detection method for UA, grouping of each study, sample size of each group, and the NOS score. Accordingly, 16 studies were conducted in Asia (22, 23, 29-32, 34-38, 40, 42-45), and other studies were conducted in Africa (28, 33, 41), Europe (39), and South America (20). In addition, two studies were based on type 1 diabetes (20, 39) with 2,311 included participants, and the others were based on type 2 diabetes (22, 29-38, 40, 43-45) and both types of diabetes (23, 28, 32, 41, 42). The colorimetric method has been used in most studies to measure UA concentrations, and only one study applied the high-performance liquid chromatography (HPLC) method (34). Except for three studies (28, 34, 39) that measured UA concentrations using plasma, serum was utilized for the measurement of UA concentrations in other studies. Eleven studies (20, 22, 29, 34, 35, 37-40, 43, 44) that scored 7 or higher were considered high quality, and others (23, 28, 30-33, 36, 41, 42, 45) scored from 4 to 6, indicating that the overall quality of the studies was acceptable. The participants' characteristics, including age, sex, and BMI, are summarized in Table 1.

Comparison of UA Levels Between Patients With DR and Controls

An obvious heterogeneity was observed among the 21 included studies ($I^2 = 97\%$; P < 0.001); thus, the random-effects model was used. We found that patients with DR had significantly higher UA levels UA than those in the controls with diabetes (WMD = 36.28; 95% CI: 15.68, 56.89; P < 0.001) (Figure 2A). Compared with healthy participants, the UA levels in patients with DR were higher (WMD = 70.80; 95% CI: 19.85, 121.75; P = 0.006; $I^2 = 98\%$; P < 0.001) (Figure 2B).

Comparison of UA Levels Between Different Phases of DR and Controls With Diabetes

The UA levels were significantly higher in participants with PDR (WMD = 46.57; 95% CI: 28.51, 64.63; P < 0.001; $I^2 = 71\%$; P

TABLE 1 | Characteristics of included studies in the meta-analysis.

References	Region	Diabetes types	Detecting methods	Specimen types	Case group (N)/control group (N)	Male (%) (DR/DM/healthy)	Age (years) (range/mean ± SD) (DR/DM/healthy)	BMI (kg/m²) (mean ± SD) (DR/DM/healthy)	NOS
Yanko et al. (23)	Israel	Both	NA	Serum	DR (64)/DM (104)	100/100/	>40	NA	5
Olukoga et al. (28)	Nigeria	Both	Colorimetric	Plasma	(145)) DR (30)/DM (145)+Healthy (114)	//48.2	20–70	//24.52 ± 4.82	6
Weitzman et al. (29)	Israel	2	NA	Serum	DR (124)/DM (367)	NA	65 ± 9.4/64.1 ± 0.7/	28.4 ± 3.9/28.8 ± 4.8/	7
Huang et al. (30)	Taiwan	2	Colorimetric	Serum	DR (91)/DM (166)+Healthy (204)	//43.1	//58.2 ± 12.2	NA	5
[-0.5pt] Cai et al. (31)	China	2	Colorimetric	Serum	NPDR (59)+PDR (28)/DM (103)	48.3/49.5/	61.7 ± 17.4/53.6 ± 13.6/	24.6 ± 3.7/25.1 ± 3.5/	6
Navin et al. (32)	India	Both	Colorimetric	Serum	NPDR (21)+PDR (13)/DM (30)+Healthy (30)	NA	NA	NA	4
Longo- Mbenza et al. (33)	DR Congo	2	NA	Serum	DR (66)/DM (84)+Healthy (45)	39.4/46.4/46.7	53.4 ± 13.6/56.6 ± 12.4/50.7 ± 13.0	$25.2 \pm 5/26.3 \\ \pm 5.0/22.4 \pm \\ 2.9$	6
Xia et al. (34)	China	2	HPLC	Plasma	NPDR (39)/DM (35)+Healthy (41)	53.8/57.1/55	$56.5 \pm$ 5.4/55.87 \pm 7.0/54.4 \pm 5.4	25.2 ± 4.0/25.1 ± 2.6/	7
Chuengsamarn et al. (35)	Thailand	2	Colorimetric	Serum	DR (154)/DM (452)	NA	NA	NA	7
Venkatachalam et al. (36)	India	2	Colorimetric	Serum	NPDR (10)+PDR (15)/DM (25)+Healthy (50)	64/56/46	$\begin{array}{c} 64.6 \pm \\ 8.8/57.6 \pm \\ 7.8/52.9 \pm \\ 6.9 \end{array}$	NA	5
Cui et al. (37)	China	2	Colorimetric	Serum	DR (141)/DM (1,608)	55.5/55.6/	57.1 ± 10.3/55.9 ± 11.3/	25.9 ± 2.9/26.3 ± 3.7/	8
Zhang et al. (38)	China	2	Colorimetric	Serum	DR (533)/DM (209)	56.3/56.9/	59.7 ± 10.5/59.2 ± 10.9/	25.1 ± 2.6/24.9 ± 3.4/	7
Pilemann- Lyberg et al. (39)	Denmark	1	Colorimetric	Plasma	NPDR (277)+PDR (229)/DM (142)	NA	NA	NA	7
Melo et al. (20)	Brazil	1	Colorimetric	Serum	DR (589)/DM (1,055)	58.2/54.4/	35.8 ± 11.6/26.9 ± 11.1/	25.1 ± 4.7/23.7 ± 3.8/	8
Chen et al. (40)	China	2	Colorimetric	Serum	NPDR (184)+PDR (162)/DM (172)	52.0/51.2/	52.8 ± 11.8/49.2 ± 8.5/	23.2 ± 3.5/23.1 ± 1.6/	7

(Continued)

TABLE 1 | Continued

References	Region	Diabetes types	Detecting methods	Specimen types	Case group (N)/control group (N)	Male (%) (DR/DM/healthy)	Age (years) (range/mean ± SD) (DR/DM/healthy)	BMI (kg/m²) (mean ± SD) (DR/DM/healthy)	NOS
Xia et al. (22)	China	2	Colorimetric	Serum	NPDR (582)+PDR (135)/DM (2,244)	46.4/52.0/	62.0 ± 10.0/60.0 ± 11.0/	NA	8
Shawki et al. (41)	Egypt	Both	Colorimetric	Serum	DR (70)/DM (40)+Healthy (40)	43/35/30	43.0 ± 10.7/45.4 ± 15.1/42.6 ± 9.4	32.4 ± 6.9/31.7 ± 6.7/30.8 ± 5.9	6
Çakir et al. (42)	Turkey	Both	Colorimetric	Serum	DR (68)/DM (54)+Healthy (42)	NA	63.4 ± 11.8/61.5 ± 11.2/59.3 ± 10.1	NA	5
Wakasugi et al. (43)	Japan	2	NA	Serum	NPDR (183)+PDR (39)/DM (777)	56.8/62/	66.0 ± 9.0/64.1 ± 9.8/	24.7 ± 3.9/24.6 ± 3.8/	7
Nakayama et al. (44)	Japan	2	Colorimetric	Serum	NPDR (72)/DM (142)	43/62/	64.0 ± 13.0/63.0 ± 10.0/	25.6 ± 4.5/25.6 ± 4.2/	7
Zhao et al. (45)	China	2	NA	Serum	NPDR (239)+PDR (104)/DM (75)	65/52/	51.7 ± 15.4/51.8 ± 14.3/	NA	6

DM, Diabetes mellitus (without diabetic retinopathy when being used as controls); DR, diabetic retinopathy; PDR, proliferative diabetic retinopathy; NPDR, non-proliferative diabetic retinopathy; NPR, non-diabetic retinopathy; HPLC, high-performance liquid chromatography; BMI, body mass index; SD, standard deviation; DR Congo, The Democratic Republic of the Congo; NA, not available; NOS, Newcastle–Ottawa scale.

= 0.001) than those in the controls with diabetes (Figure 3A); however, when comparing UA levels in patients with NPDR and controls with diabetes, the difference is not statistically significant (WMD = 22.50; 95% CI:-6.07, 51.08; P = 0.120; $I^2 = 97\%$; P < 0.001) (Figure 3B).

Comparison of UA Levels Between PDR and NPDR

Eight studies (22, 31, 32, 36, 39, 40, 43, 45) divided patients with DR into PDR and NPDR groups. There were significant differences in UA levels between patients with PDR and NPDR in a fixed-effects model (WMD = 28.68; 95% CI: 19.78, 37.58; *P* < 0.001; $I^2 = 44\%$; *P* = 0.090) (Figure 3C).

Subgroup and Meta-Regression Analyses

Table 2 presents the results of the subgroup analyses of UA levels between patients with DR and controls with diabetes. Most of the subgroup analysis results were consistent with the overall metaanalysis results, suggesting that these results were relatively stable but with high heterogeneity. Subgroup analyses of the region and diabetes type reported that UA levels were lower in Asians (WMD = 24.67; 95% CI: 2.30, 47.03; P = 0.031) and participants with type 2 diabetes (WMD = 27.16; 95% CI: 2.61, 51.71; P = 0.030). Increased UA levels were not significant in studies including both types of diabetes (WMD = 60.51; 95% CI: -19.27, 140.29; P = 0.137) and studies using plasma for UA measurement (WMD = 50.15; 95% CI: -1.42, 101.72; P = 0.057). When stratified by quality score (NOS <7 and NOS \geq 7), the results showed that the heterogeneity failed to decrease in studies where NOS <7 with an I^2 of 95.5%, and in NOS \geq 7 studies, the I^2 was 97.6%. The results were statistically significant in NOS <7 (WMD = 42.26; 95% CI: 1.14, 83.38; P = 0.044) and NOS ≥ 7 (WMD = 33.15; 95% CI: 7.45, 58.84; P = 0.011). Further subgroup analyses demonstrated increased UA levels in participants with a longer duration of diabetes (WMD = 62.22; 95% CI: 19.16, 105.27; P = 0.005), higher BMI (WMD = 63.51; 95% CI: 13.11, 113.91; *P* < 0.001), FBG (WMD = 52.76; 95% CI: 10.15, 95.37; P = 0.015), HbA_{1c} (WMD = 55.35; 95% CI: 23.92, 86.78; P =0.001), and LDL (WMD = 55.39; 95% CI: 37.11, 79.67; P <0.001). In addition, we divided the UA concentrations in patients with DR [median: 333; interquartile range (IQR): 307.1-378.15, mg/dL] by quartile. The subgroup analysis of UA levels showed an insignificant difference in quartile 1 (WMD = 3.72; 95% CI: -32.87, 40.32; P = 0.842), while in quartiles 2-4, especially in quartile 4, there was an increase in UA levels (WMD = 128.06; 95% CI: 72.37, 183.75; *P* < 0.001) (Figure 4).

According to the findings of subgroup analyses, a univariate meta-regression analysis regarding the clinical characteristics of participants, including BMI, duration of DM, FBG, HbA_{1c}, and LDL, was performed to identify possible impact factors on the



⁽A)/without (B) diabetes. WMD, weighted mean difference; UA, uric acid.

relationship between UA and DR. The results showed that BMI (P = 0.007, Adj $R^2 = 40.12\%$) and FBG levels (P = 0.040, Adj $R^2 = 29.72\%$) could explain the variation in study results, whereas the duration of DM (P = 0.099, Adj $R^2 = 14.93\%$), LDL (P = 0.308, Adj $R^2 = 0.61\%$), and HbA_{1c} (P = 0.537, Adj $R^2 = -5.43\%$) were not significant for determining the source of heterogeneity.

Sensitivity Analysis and Publication Bias

To evaluate the stability and reliability of our results, we performed a sensitivity analysis that excluded one study from the meta-analysis. After the included studies were successively removed, the estimates were statistically significant with WMD ranging from 24.46 (95% CI: 5.85, 43.07) to 39.91 (95% CI: 19.15, 60.68), indicating that the overall results were relatively stable (**Figure 5**). Notably, there was a marked decrease (though still obvious) in heterogeneity among studies when two sensitive studies (34, 41) were removed (WMD = 19.50; 95% CI: 5.87, 33.12; P = 0.005; $I^2 = 91\%$; P < 0.001),

suggesting these two studies contributed relatively more to the heterogeneity.

The Egger funnel plot of the results of the included studies was symmetrical (**Supplementary Material**). The *P*-values of Begg's and Egger's tests of publication bias analyses were 0.291 and 0.156, respectively, suggesting that statistically significant publication bias.

DISCUSSION

To provide a better understanding of the relationship between UA and DR. We conducted a systematic review and meta-analysis to compare differences in UA levels between patients with DR and controls. We also tested whether UA levels could differ in different phases of DR, including NPDR and PDR. To the best of our knowledge, this is the first meta-analysis to show an exact association using MD with 95% CIs.

The results of our meta-analysis showed that UA levels in patients with DR were significantly higher than those in

Cai et al.(2006) 337.6 115.1 28 288.5 90.9 103 8.6% 49.10 [2.99, 95.21] 2006 Navin et al.(2013) 276 33.3 13 254 28 30 15.7% 22.00 [1.31, 42.69] 2013 Venkatachalam et al.(2017) 423.5 178.4 15 309.1 112.1 25 2.8% 114.40 [13.99, 214.81] 2017 Pilemann-Lyberg et al.(2018) 330 133.3 229 250 81.5 142 15.4% 80.00 [58.14, 101.86] 2018 Xia et al.(2020) 358 108 135 331 100 2244 16.3% 27.00 [8.32, 45.68] 2020 Chen et al.(2020) 421.5 112.4 162 80.7 100.2 172 15.0% 60.80 [37.91, 83.69] 2020 Wakasugi et al.(2021) 333.9 78.1 39 306.6 72.3 777 14.3% 27.30 [2.27, 52.33] 2021 Zhao et al.(2021) 372.1 142.1 104 321.7 85.8 75 11.8% 50.40 [16.89, 83.91] 2021 Total (95% CI)	Study or Subgroup	Mean	with PD			thout D		Veight	Mean Difference IV, Random, 95%	CI Voar	Mean Differe	
Navine tai (2013) 276 33.3 13 254 28 30 15.7% 22.00 [1.31, 42.69] 2013 Verketachalam et al.(2017) 325 178.4 15 306.1 112 25 2.28 114.0 [1.39, 214.81] 2017 Pleman-Lyberg et al.(2018) 330 133.3 229 250 61.5 142 15.4% 60.00 [55.14, 101.66] 2016 Xia et al.(2020) 421.5 112.4 162 360.7 100.2 217 15.0% 60.80 [37.91, 83.69] 2020 Wakasugi et al.(2021) 33.9 76.1 39 306.6 72.3 777 14.3% 27.30 [2.27, 22.33] 2021 Total (95% CI) 725 3568 100.0% 46.57 [28.51, 64.63] Heterogeneity: Tau" = 428.67; Ch ^p = 23.79, dt = 7 (P = 0.01); P = 71% Test for overall effect Z = 5.05 (P < 0.00001); P = 0.001; P = 71% Test for overall effect Z = 5.05 (P < 0.00001); P = 71% Test for overall effect Z = 5.05 (P < 0.00001); P = 71% Study or Subgroup Mean SD Total Mean SD Total Mean SD Total Mean SD Total 9.95 [0.07, 61.08, 24] 2013 Navin et al.(2013) 257 19.6 21 254 28 30 10.7% 18.01 [-50.84, 31] 2021 Total (95% CI) 7 16.6 21 254 28 30 10.7% 18.01 [-50.84, 31] 2017 Plemann-Lyberg et al.(2018) 335 106 582 331 100 2244 11.35 10.80% 95.5 [0.67, 61.08, 24] 2013 Xia et al.(2017) 326 106.1 10 309.1 112.1 25 6.0% 16.09.162.19, 95.99] 2017 Plemann-Lyberg et al.(2018) 333 89.22 77 250 81.5 142 106.6% 30.00 [153.14.64.99] 2017 Plemann-Lyberg et al.(2018) 335 106 582 331 100 2244 10.8% 4.00 [-55.7, 13.59] 2020 Xia et al.(2021) 337.4 190.9 184 360.7 100.2 172 10.4% 36.70 [16.78, 64.89] 2017 Plemann-Lyberg et al.(2018) 333 89.22 7 2 345 89.22 142 10.17% 24.80 [15.28, 73.5] 2021 Total (95% CI) 65 21 254 95.2 21 42 10.17% 24.80 [15.28, 73.5] 2021 Total (95% CI) 65 33 31 100 259 42.5 10.0% 95.5 [0.67, 51.56] Heterogeneity: Tau" = 1940.68; Ch ^p = 27.87, df = 9 (P < 0.0001); P = 97% Test for overall effect Z = 1.54 (P = 10.2) Total (95% CI) 72 33 97.4 19.2 19.2 30.73, 50.01, 30.01 2021 Total (95% CI) 72 33 97.4 19.2 19.2 30.73, 50.00 [2.56, 47.5] Navin et al.(2021) 33.1 229 200 81.5 277 20.3% 50.00 [2.56, 47.5] Navin et al.(2021) 33.3 13 3 22.2 200 81.5 277 20.3% 50.00 [2.64.7, 51.69] Heterogeneity: Tau" = 1940.68; Ch ^p = 27.97, df =								-				
$\begin{tabular}{ c c c c c c c c c c c c c c c c c c c$												
$\begin{array}{c c c c c c c c c c c c c c c c c c c $										-		
Xia et al. (2020) 358 108 135 331 100 2244 16.3% 27.0 [8.2 4.56 [2020] 42.15 1124 162 380.7 1002 172 156% 60.8 (37.9 18.36 [2020] 42.15 1124 162 380.7 1002 172 156% 60.8 (37.9 18.36 [2020] 44.5 10.2 172 156% 60.8 (37.9 18.36 [2020] 44.5 10.2 172 156% 60.8 (37.9 18.36 [2020] 44.5 10.2 172 156% 60.8 (37.9 18.36 [2020] 44.5 10.2 172 15.8 (5.6 10.0.0\% 46.5 [28.51, 64.63] 44.6 (16.6.9, 83.9 1] 2021 170 14 [95% C] 172 33.9 78.1 39 30.6 72.3 777 14.3% 27.3 (12.27, 52.33) 2021 100 $\frac{1}{50} - \frac{50}{50} - \frac{50}{50} - \frac{1}{100} \frac{1}{50} - \frac{50}{50} - \frac{50}{50} - \frac{1}{100} - \frac{50}{50} - \frac{50}{50} - \frac{50}{50} - \frac{1}{100} - \frac{50}{50} - \frac{50}{50} - \frac{50}{50} - \frac{1}{100} - \frac{50}{50} - 50$	· · ·											
Chen et al (2020) 421.5 112.4 162 380.7 100.2 172 15.0% 60.80 [379.18.86] 2020 Wakasugi et al (2021) 333 78.1 39 30.6 72.3 777 14.3% 27.30 [2.27, 52.33] 2021 Total (95% CI) 725 3568 100.0% 46.57 [28.51, 64.63] Heterogeneity: Tau ² = 428.67; Ch ² = 23.79; df = 7 (P = 0.001); P = 71% Total (95% CI) 725 3568 100.0% 46.57 [28.51, 64.63] Heterogeneity: Tau ² = 5.05 (P < 0.00001) Maxim et al (2013) 30.3 102 59 288.5 90.9 103 9.7% 11.80 [-19.59, 43.19] 2006 Navin et al (2013) 30.3 102 59 288.5 90.9 103 9.7% 11.80 [-19.59, 43.19] 2006 Navin et al (2014) 236 106.1 10 309.1 112.1 25 6.0% 16.50 (-19.95.59] 2011 Venkatacham et al (2017) 325 19.6 21 254 28 30 10.7% 3.00 (13.51, 46.49] 2018 Chen et al (2020) 337 102 59 288.5 90.9 103 9.7% 11.80 [-19.59, 43.19] 2006 Navin et al (2013) 226 106.1 10 309.1 112.1 25 6.0% 16.50 (-15.9, 95.99] 2011 Venkatacham et al (2017) 326 106.1 10 309.1 112.1 25 6.0% 16.50 (-15.9, 95.99] 2014 Venkatacham et al (2017) 331 47 92.2 183 306.6 72.3 777 10.7% 24.80 [12.52, 37.35] 2020 Total (95% CI) 1666 3745 100.0% 22.50 [-6.07, 51.08] Heterogeneity: Tau ² = 1940.68; Ch ² = 297.87, f = 9 (P < 0.00001); P = 97% Test for overall effect: Z = 1.54 (P = 0.12) Divid with PDR DM with NDR Mean Difference Nean Difference IV. Fixed, 95% CI Total (95% CI) 1666 3745 100.0% 22.50 [-4.75, 30.85] Navin et al (2021) 33.5 19.2 72 345 89.2 2142 10.1% 1.20 (-37.30, 13.30] 2021 Total (95% CI) 606 37.6 115.1 28 300.3 102 59 3.2% 37.30 (-12.65, 67.25] Navin et al (2021) 37.6 115.1 28 300.3 102 59 3.2% 37.30 (-12.65, 67.25] Navin et al (2021) 37.6 115.1 28 300.3 102 59 3.2% 37.30 (-12.65, 67.25] Navin et al (2021) 37.6 115.1 12.8 305.3 106 582 19.5% 2.300 (28.5, 61.75] Navin et al (2021) 37.6 115.1 28 300.3 102 59 3.2% 37.30 (-12.65, 67.75] Navin et al (2021) 37.6 115.1 12.8 300.3 102 59 3.2% 37.30 (-12.65, 67.75] Navin et al (2021) 37.6 115.1 28 300.3 102 59 3.2% 37.30 (-12.65, 67.75] Navin et al (2021) 37.6 115.1 28 300.3 102 59 3.2% 37.00 (-13.65, 67.75] Navin et al (2021) 37.6 17.5 1											_	
Wakesugi et al. (2021) 333.9 78.1 39 306.6 72.3 777 14.3% 27.30 [22.7, 52.3] 2021 Zhao et al. (2021) 372.1 142.1 104 321.7 85.8 75 11.8% 50.40 [16.89, 83.91] 2021 Total (95% CI) 725 3568 100.0% 46.57 [28.51, 64.63] -100 -50 50 1 Heterogeneity: Tau" = 428.67; ChF = 23.79, df = 7 (P = 0.001); P = 71% DM with NDR DM without DR Mean Difference Mean Difference Mean Difference Mean Difference Nandom. 95% CI = 1 100 -50 50 1 Study or Subgroup Mean 257 126.6 309 10.1 43.0 10.7% 3.00 [-10.61, flo.61 210 24.4 10.8% 95.0 10.7% 3.00 [-10.61, flo.61 210 24.4 10.8% 95.0 21.4 4.00 [-55.51, 35.5] 2021 Plemann-Lyberg et al.(2021) 335 106 582 331 100 24.4 10.8% 4.00 [-57.51, 35.5] 2021 10.4 4.00 [-57.51, 35.5] 2021 10.4 4.00 [-57.51, 35.5] 2021 <										-		
Zhao et al. (2021) 372.1 142.1 104 321.7 85.8 75 11.8% 50.40 [16.89, 83.91] 2021 Total (95% CI) 725 3568 100.0% 46.57 [28.51, 64.63] -100 -50 50 1 Test for overall effect: Z = 5.05 (P < 0.0001)												
Total (95% CI) 725 3568 100.0% 46.57 [28.51, 64.63] Total (95% CI) 725 3568 100.0% 46.57 [28.51, 64.63] Test for overall effect: $Z = 5.05$ ($P < 0.0001$); $P = 71\%$ Test for overall effect: $Z = 5.05$ ($P < 0.0001$) Mean DIfference Mean Difference V. Random .95% CI Ver V. Random .95% CI V. Random .95% CI V. Random .95% CI V. Random .95% CI V. V. Random	• • •									-		
Heterogeneily: Tau ² = 428.67; Ch ² = 23.79, df = 7 (P = 0.01); P = 71% Test for overall effect: Z = 5.05 (P < 0.00001) $ \begin{array}{c ccccccccccccccccccccccccccccccccccc$	Zhao et al.(2021)	372.1	142.1	104 ,	521.7	00.0	75	11.0%	50.40 [16.69, 63.9	1] 2021		
Test for overall effect: Z = 5.05 (P < 0.00001) 50 0 1 Favours low UA Favours high UA DM with NPDR DM without DR Mean Difference Mean Difference Study or Subgroup Mean SD Total Mean SD Total Weight V. Random, 95% CI Year IV. Random, 95%, CI Cai et al (2006) 300.3 100 5 50 0 1 SUGY of Subgroup Mean SD Total Mean SD Total Mean SUGY of Subgroup Mean SD Total Mean SU Total Mean SD Total Mean SU Total Mean SD Total Mean	Total (95% CI)			725		;	3568 1	00.0%	46.57 [28.51, 64.63]		-
Total Weight V2.00001) Favours low UA Favours high UA Study or Subgroup Mean SD Total Mean SD Total Weight IV. Random, 95% CI Year Cai et al.(2006) 300.3 102 Favours high UA SD Total Mean SD Total Mean SD Total Mean Difference Mean SD Total Mean <t< td=""><td></td><td></td><td></td><td>: 7 (P =</td><td>0.001);</td><td>l² = 71%</td><td>6</td><td></td><td></td><td></td><td>-100 -50 0</td><td>50 100</td></t<>				: 7 (P =	0.001);	l² = 71%	6				-100 -50 0	50 100
DM with NPDR DM without DR Mean Difference Mean Difference Mean Difference IV. Random, 95%, CI Cai et al.(2006) 300.3 102 59 28.5 90.9 103 9.7% 11.80 [-19.59, 43.19] 2006 Navin et al.(2013) 257 19 28.5 90.9 103 9.7% 11.80 [-19.59, 43.19] 2006 Xia et al.(2014) 419.6 23.6 39 320.1 14 35 10.8% 99.50 [90.67, 108.24] 2014 Venkatachalam et al.(2017) 326 106 10 309.1 112.1 25 6.0% 30.00 [13.51, 46.49] 2018 Chen et al.(2020) 335 106 52.33 100.2 172 10.4% 30.00 [13.51, 46.49] 2018 Nakayama et al.(2021) 331.4 79.2 183 306.6 72.3 777 10.7% 24.80 [12.25, 37.35] 2021 Nakayama et al.(2021) 331.4 79.2 185 89.22 142 10.1% .12.00 [-37.30, 13.0]	Test for overall effect: Z = 5.05	(P < 0.0	0001)									
DM with NPDR DM without DR Mean SD Total SD Total Mean SD Total Mean SD Total Mean SD Total Mean SD Total SD Total	1											
$\begin{array}{c c c c c c c c c c c c c c c c c c c $												
Navin et al. (2013) 257 19.6 21 254 28 30 10.7% 3.00 [-10.06, 16.06] 2013 Xia et al. (2014) 419.6 23.6 39 320.1 14 35 10.8% 9.50 [90.76, 108.24] 2014 Venkatachalam et al. (2017) 326 106.1 10 309.1 112.1 25 6.0% 16.90 [62.19, 95.99] 2017 Pilemann-Lyberg et al. (2018) 280 81.5 277 250 81.5 142 10.6% 30.00 [13.51, 46.49] 2018 Chen et al. (2020) 397.4 90.9 184 360.7 100.2 172 10.4% 36.70 [16.78, 56.62] 2020 Wakasugi et al. (2021) 331.4 79.2 183 306.6 72.3 777 10.7% 24.80 [12.25, 37.35] 2021 Total (2021) 325.4 96.2 239 321.7 85.8 75 10.2% 3.70 [16.78, 56.63] 2021 Total (95% CI) 1666 3745 100.0% 22.50 [-6.07, 51.08] Heterogeneity: Tau ² = 1940.68; Ch ² = 297.87, df = 9 (P < 0.00001); ² = 97% Test for overall effect: Z = 1.54 (P = 0.12) DM with PDR DM with NPDR Mean Difference Study or Subgroup Mean SD Total Mean SD Total Weight IV. Fixed, 95% CI IV. Fixed, 95% CI IV. Fixed, 95% CI V. Fixed, 95% CI IV. Fixed, 95% CI I	Study or Subgroup	Mean	SD	Total	Mean	SD	Total \	Neight	IV, Random, 95%	CI Year	IV, Random, 9	5% CI
Xia et al. (2014) 419.6 23.6 39 320.1 14 35 10.8% 99.50 [90.76, 108.24] 2014 Venkatachalam et al. (2017) 326 106.1 10 309.1 112.1 25 6.0% 16.09 [62.19, 95.99] 2017 Pilemann-Lyberg et al. (2018) 280 81.5 277 250 81.5 142 10.6% 30.00 [13.51, 146.49] 2018 Chen et al. (2020) 397.4 90.9 184 360.7 100.2 172 10.4% 36.70 [16.78, 56.62] 2020 Xia et al. (2021) 331.4 79.2 183 306.6 72.3 777 10.7% 24.80 [12.25, 37.35] 2021 Nakayama et al. (2021) 326.4 96.2 239 321.7 85.8 75 100.2% 3.70 [-19.23, 26.63] 2021 Nakayama et al. (2021) 333 89.22 72 345 89.22 142 10.1% -12.00 [-37.30, 13.30] 2021 Total (95% Cl) 1666 3745 100.0% 22.50 [-6.07, 51.08] Heterogeneity: Tau ² = 1940.68; Chi ² = 297.87, df = 9 (P < 0.00001); I ² = 97% Test for overall effect: Z = 1.54 (P = 0.12) DM with PDR DM with NPDR Mean Difference Mean Difference Study or Subgroup Mean SD Total Mean SD Total Weight IV. Fixed, 95% Cl Cai et al. (2020) 337.6 115.1 28 300.3 102 59 3.2% 37.30 [-12.65, 87.25] Venkatachalam et al. (2017) 423.5 178.4 15 326 106.1 10 0.6% 97.50 [-14.19, 209.19] Pilemann-Lyberg et al. (2018) 330 133.3 229 280 81.5 277 20.3% 50.00 [30.25, 69.75] Chen et al. (2020) 421.5 112.4 162 397.4 90.9 184 16.8% 24.10 [2.37, 45.83] Wakasugi et al. (2021) 332.9 78.1 39 331.4 79.2 183 10.8% 2.50 [-24.56, 29.56] Zhao et al. (2021) 332.9 78.1 39 331.4 79.2 183 10.8% 2.50 [-24.56, 29.56] Zhao et al. (2021) 37.2 1 142.1 104 325.4 96.2 239 8.9% 46.70 [16.79, 76.61] Total (95% Cl) 725 1555 100.0% 28.68 [19.78, 37.58] Heterogeneity: Chi ² = 12.42, df = 7 (P = 0.09); I ² = 44% Total (95% Cl) 725 1555 100.0% 28.68 [19.78, 37.58] Heterogeneity: Chi ² = 12.42, df = 7 (P = 0.09); I ² = 44%	Cai et al.(2006)	300.3	102	59	288.5	90.9	103	9.7%	11.80 [-19.59, 43.19] 2006		
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Navin et al.(2013)	257	19.6	21	254	28	30	10.7%	3.00 [-10.06, 16.06] 2013		
Pilemann-Lyberg et al. (2018) 280 81.5 277 250 81.5 142 10.6% 30.00 [13.51, 46.49] 2018 Chen et al. (2020) 397.4 90.9 184 360.7 10.0.2 172 10.4% 36.70 [16.78, 56.62] 2020 Xia et al. (2020) 335 106 582 331 100 2244 10.8% 4.00 [5.55, 13.55] 2020 Wakasugi et al. (2021) 331.4 79.2 183 306.6 72.3 777 10.7% 24.80 [12.26, 37.36] 2021 Nakayama et al. (2021) 325.4 96.2 239 321.7 85.8 75 10.2% 3.70 [19.23, 26.63] 2021 Nakayama et al. (2021) 333 89.22 72 345 89.22 142 10.1% -12.00 [-37.30, 13.30] 2021 Total (95% Cl) 1666 3745 100.0% 22.50 [-6.07, 51.08] Heterogeneity: Tau ² = 1940.68; Chi ² = 297.87, df = 9 (P < 0.0001); l ² = 97% Test for overall effect: Z = 1.54 (P = 0.12) Maxim et al. (2013) 276 33.3 13 257 19.6 21 19.9% 37.30 [-12.65, 87.25] Navin et al. (2013) 276 33.3 13 257 19.6 21 19.9% 37.30 [-26.56, 87.25] Navin et al. (2013) 276 33.3 13 257 19.6 21 19.9% 37.30 [-26.56, 87.25] Navin et al. (2017) 423.5 178.4 15 326 106.1 10 0.6% 97.50 [-14.19, 209.19] Pilemann-Lyberg et al. (2021) 330 133.3 229 280 81.5 277 20.3% 50.00 [30.25, 69.75] Chen et al. (2020) 358 108 135 335 106 582 19.5% 23.00 [2.85, 43.15] Xia et al. (2021) 332.9 78.1 39 331.4 79.2 183 10.8% 22.50 [-24.56, 29.56] Total (95% Cl) 725 155 100.0% 28.68 [19.78, 37.58] Heterogeneity: Chi ² = 12.42, df = 7 (P = 0.09); l ² = 44% Total (95% Cl) 725 155 100.0% 28.68 [19.78, 37.58] Heterogeneity: Chi ² = 12.42, df = 7 (P = 0.09); l ² = 44%	Xia et al.(2014)	419.6	23.6	39	320.1	14	35	10.8%	99.50 [90.76, 108.24] 2014		_
Chen et al. (2020) $397.4 \ 90.9 \ 184 \ 360.7 \ 100.2 \ 172 \ 10.4\% \ 36.70 \ [16.78, 56.62] \ 2020$ Xia et al. (2020) $335 \ 106 \ 582 \ 331 \ 100 \ 2244 \ 10.8\% \ 4.00 \ [-5.55, 13.55] \ 2020$ Wakasugi et al. (2021) $331.4 \ 79.2 \ 183 \ 306.6 \ 72.3 \ 777 \ 10.7\% \ 24.80 \ [12.25, 37.35] \ 2021$ Nakayama et al. (2021) $333 \ 89.22 \ 72 \ 345 \ 89.22 \ 142 \ 10.1\% \ -12.00 \ [-37.30, 13.30] \ 2021$ Total (95% CI) $1666 \ 3745 \ 100.0\% \ 22.50 \ [-6.07, 51.08]$ Heterogeneity: Tau ² = 1940.68; Chi ² = 297.87, df = 9 (P < 0.00001); l ² = 97% Test for overall effect: Z = 1.54 (P = 0.12) Main et al. (2017) $1676 \ 337.6 \ 115.1 \ 28 \ 300.3 \ 102 \ 59 \ 3.2\% \ 37.30 \ [-12.65, 87.25] \ Navin et al. (2017) \ 423.5 \ 178.4 \ 15 \ 326 \ 106.1 \ 10 \ 0.6\% \ 97.50 \ [-14.19, 209.19] \ Pilemann-Lyberg et al. (2018) \ 330 \ 133.3 \ 229 \ 280 \ 81.5 \ 277 \ 20.3\% \ 50.00 \ [30.25, 69.75] \ Navin et al. (2020) \ 421.5 \ 112.4 \ 162 \ 397.4 \ 90.9 \ 184 \ 16.8\% \ 24.10 \ [2.37, 45.83] \ Xia et al. (2021) \ 372.1 \ 142.1 \ 104 \ 325.4 \ 96.2 \ 239 \ 8.9\% \ 46.70 \ [16.79, 76.61] \ Makasugi et al. (2021) \ 372.1 \ 142.1 \ 104 \ 325.4 \ 96.2 \ 239 \ 8.9\% \ 46.70 \ [16.79, 76.61] \ -100 \ -50 \ 0 \ 50 \ 100 \ -100 \ -50 \ 0 \ 50 \ 100 \ -100 \ -50 \ 0 \ 50 \ 100 \ -100 \ -50 \ 0 \ 50 \ 100 \ -100 \ -50 \ 0 \ 50 \ 100 \ -100 \ -50 \ 0 \ 50 \ 100 \ -100 \ -50 \ 0 \ 50 \ 100 \ -100 \ -50 \ 0 \ 50 \ 100 \ -100 \ -50 \ 0 \ 50 \ 100 \ -100 \ -50 \ 0 \ 50 \ 100 \ -100 \ -50 \ 0 \ 50 \ 100 \ -100 \ -50 \ 0 \ 50 \ 100 \ -100 \ -50 \ 0 \ 50 \ 100 \ -100 \ -50 \ 0 \ 50 \ 100 \ -100 \ -50 \ 0 \ 50 \ 100 \ -100 \ -50 \ 0 \ 50 \ 100 \ -100 \ -50 \ 0 \ 50 \ 100 \ -100 \ -50 \ -$	Venkatachalam et al.(2017)	326	106.1	10	309.1	112.1	25	6.0%	16.90 [-62.19, 95.99] 2017		
Xia et al.(2020) 335 106 582 331 100 2244 10.8% 4.00 [-5.55, 13.55] 2020 Wakasugi et al.(2021) 331.4 79.2 183 306.6 72.3 777 10.7% 24.80 [12.25, 37.35] 2021 Zhao et al.(2021) 325.4 96.2 239 321.7 85.8 75 10.2% 3.70 [-19.23, 26.63] 2021 Nakayama et al.(2021) 333 89.22 72 345 89.22 142 10.1% -12.00 [-37.30, 13.30] 2021 Total (95% Cl) 1666 3745 100.0% 22.50 [-6.07, 51.08] Heterogeneity: Tau ² = 1940.68; Chi ² = 297.87, df = 9 (P < 0.00001); I ² = 97% Test for overall effect: Z = 1.54 (P = 0.12) Main et al.(2013) 276 33.3 13 257 19.6 21 19.9% 19.00 [-0.95, 38.95] Venkatachalam et al.(2017) 423.5 178.4 15 326 106.1 10 0.6% 97.50 [-14.19, 209.19] Pilemann-Lyberg et al.(2021) 333.9 78.1 39 331.4 79.2 183 10.8% 2.50 [-24.56, 29.56] Zhao et al.(2021) 37.2 1142.1 104 325.4 96.2 239 8.9% 46.70 [16.79, 76.61] Total (95% Cl) 725 155 100.0% 28.68 [19.78, 37.58] Heterogeneity: Chi ² = 12.42, df = 7 (P = 0.09); P = 44% Total (95% Cl) 725 155 100.0% 28.68 [19.78, 37.58]	Pilemann-Lyberg et al.(2018)	280	81.5	277	250	81.5	142	10.6%	30.00 [13.51, 46.49] 2018	-	
Wakasugi et al. (2021) 331.4 79.2 183 306.6 72.3 777 10.7% 24.80 [12.25, 37.35] 2021 Zhao et al. (2021) 325.4 96.2 239 321.7 85.8 75 10.2% 3.70 [-19.23, 26.63] 2021 Nakayama et al. (2021) 333 89.22 72 345 89.22 142 10.1% -12.00 [-37.30, 13.30] 2021 Total (95% Cl) 1666 3745 100.0% 22.50 [-6.07, 51.08] -100 -50 0 50 100 Heterogeneity: Tau ² = 1940.68; Chi ² = 297.87, df = 9 (P < 0.00001); I ² = 97% Velocities in the second of the second	Chen et al.(2020)	397.4	90.9	184	360.7	100.2	172	10.4%	36.70 [16.78, 56.62] 2020	-	
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Xia et al.(2020)	335	106	582	331	100	2244	10.8%	4.00 [-5.55, 13.55] 2020	+	
Nakayama et al. (2021) 333 89.22 72 345 89.22 142 10.1% -12.00 [-37.30, 13.30] 2021 Total (95% Cl) 1666 3745 100.0% 22.50 [-6.07, 51.08] Heterogeneity: Tau ² = 1940.68; Chi ² = 297.87, df = 9 (P < 0.00001); l ² = 97% Test for overall effect: Z = 1.54 (P = 0.12) DM with PDR DM with NPDR Mean SD Total Mean SD Total Weight IV. Fixed, 95% Cl IV.	Wakasugi et al.(2021)	331.4	79.2	183	306.6	72.3	777	10.7%	24.80 [12.25, 37.35] 2021	-	
Total (95% Cl) 1666 3745 100.0% 22.50 [-6.7, 51.08] Heterogeneity: Tau ² = 1940.68; Chi ² = 297.87, df = 9 (P < 0.00001); I ² = 97% Image: the terogeneity: Tau ² = 1940.68; Chi ² = 297.87, df = 9 (P < 0.00001); I ² = 97% Image: the terogeneity: Tau ² = 1940.68; Chi ² = 297.87, df = 9 (P < 0.00001); I ² = 97% Test for overall effect: Z = 1.54 (P = 0.12) DM with PDR DM with NPDR Mean Difference Mean Difference Study or Subgroup Mean SD Total Mean SD Total Weight IV. Fixed. 95% Cl IV. Fixed. 95% Cl Cai et al.(2006) 337.6 115.1 28 300.3 102 59 3.2% 37.30 [-12.65, 87.25] Navin et al.(2013) 276 33.3 13 257 19.6 21 19.9% 19.00 [-0.95, 38.95] Venkatachalam et al.(2017) 423.5 178.4 15 326 106.1 10 0.6% 97.50 [-14.19, 209.19] 97.50 [-54.56, 29.56] Chen et al.(2020) 421.5 112.4 162 397.4 90.9 184 10.8% 2.50 [-24.56, 29.56] 100.5% 23.00 [2.85, 43.15] 100.5% 100 100 100 <	Zhao et al.(2021)	325.4	96.2	239	321.7	85.8	75	10.2%	3.70 [-19.23, 26.63] 2021		_
Heterogeneity: Tau ² = 1940.68; Chi ² = 297.87, df = 9 (P < 0.00001); l ² = 97% Test for overall effect: Z = 1.54 (P = 0.12) Mwith PDR DM with PDR Mean Difference Study or Subgroup Mean SD Total Mean SD Total Mean Difference Cl IV. Fixed, 95% Cl Colspan="6">Mean SD Total Mean SD Total Weight IV. Fixed, 95% Cl Colspan="6">Mean SD Total Mean SD Total Weight IV. Fixed, 95% Cl IV. Fixed, 95% Cl Colspan="6">Mean SD Total Mean SD Total Weight IV. Fixed, 95% Cl IV. Fixed, 95% Cl Colspan="6">Mean SD Total Mean SD Total Weight IV. Fixed, 95% Cl IV. Fixed, 95% Cl Colspan="6">Mean SD Total Mean SD Total Weight IV. Fixed, 95% Cl IV. Fixed, 95% Cl Colspan= 80.03 337.6 115.1 28 30.02 S9 3.2.% 37.00 [-14.19, 209.19] IV. Fixed, 95% Cl Venkatachalam et al.(2020) 333.6 100	Nakayama et al.(2021)	333	89.22	72	345	89.22	142	10.1%	-12.00 [-37.30, 13.30] 2021		
Heterogeneity: Tau ² = 1940.68; Chi ² = 297.87, df = 9 (P < 0.00001); l ² = 97% Test for overall effect: Z = 1.54 (P = 0.12) DM with PDR Mean Difference Study or Subgroup Mean SD Total Mean SD Total Weight IV. Fixed, 95% Cl Cl IV. Fixed, 95% Cl Cai et al.(2006) 337.6 115.1 28 Mean SD Total Weight IV. Fixed, 95% Cl Cl IV. Fixed, 95% Cl IV. Fixed, 95% Cl IV. Fixed, 95% Cl IV. Fixed, 95% Cl IV. Fixed, 95% Cl IV. Fixed, 95% Cl IV. Fixed, 95% Cl IV. Fixed, 95% Cl IV.	Total (95% CI)			1666			3745 1	100.0%	22.50 [-6.07, 51.08	1		
Test for overall effect: $Z = 1.54$ (P = 0.12) -100 -50 50 100 Favours low UA Favours high UA Sudy or Subgroup Mean SD Total Mean SD Total Mean SD Total Mean Difference	Heterogeneity: Tau ² = 1940.68	$Chi^2 = 2$	297.87. 0	f = 9 (F	< 0.00	001): l²	= 97%			•		+ +
Study or Subgroup Mean SD Total Mean SD Total Weight IV. Fixed, 95% Cl IV. Fixed, 95% Cl Cai et al.(2006) 337.6 115.1 28 300.3 102 59 3.2% 37.30 [-12.65, 87.25] IV. Fixed, 95% Cl IV. Fixed, 95% Cl Navin et al.(2013) 276 33.3 13 257 19.6 21 19.9% 19.00 [-0.95, 38.95] Venkatachalam et al.(2017) 423.5 178.4 15 326 106.1 10 0.6% 97.50 [-14.19, 209.19] Pilemann-Lyberg et al.(2018) 330 133.3 229 280 81.5 277 20.3% 50.00 [30.25, 69.75] Chen et al.(2020) 421.5 112.4 162 397.4 90.9 184 16.8% 24.10 [2.37, 45.83] Xia et al.(2020) 353.5 106 582 19.5% 23.00 [2.85, 43.15]	• •			,		,,						
Study or Subgroup Mean SD Total Mean SD Total Weight IV. Fixed. 95% Cl IV. Fixed. 95% Cl Cai et al.(2006) 337.6 115.1 28 300.3 102 59 3.2% 37.30 [-12.65, 87.25] IV. Fixed. 95% Cl IV. Fixed. 95% Cl Navin et al.(2013) 276 33.3 13 257 19.6 21 19.9% 19.00 [-0.95, 38.95] Venkatachalam et al.(2017) 423.5 178.4 15 326 106.1 10 0.6% 97.50 [-14.19, 209.19] Pilemann-Lyberg et al.(2018) 330 133.3 229 280 81.5 277 20.3% 50.00 [30.25, 69.75] Chen et al.(2020) 421.5 112.4 162 397.4 90.9 184 16.8% 24.10 [2.37, 45.83] Xia et al.(2020) 358 108 135 335 106 582 19.5% 23.00 [2.85, 43.15] Wakasugi et al.(2021) 372.1 142.1 104 325.4 96.2 239 8.9% <td< td=""><td></td><td>D</td><td>/ with F</td><td>DR</td><td>DM</td><td>with N</td><td>PDR</td><td></td><td>Mean Differen</td><td>ce</td><td>Mean Differe</td><td>nce</td></td<>		D	/ with F	DR	DM	with N	PDR		Mean Differen	ce	Mean Differe	nce
Cai et al. (2006) 337.6 115.1 28 300.3 102 59 3.2% 37.30 [-12.65, 87.25] Navin et al. (2013) 276 33.3 13 257 19.6 21 19.9% 19.00 [-0.95, 38.95] Venkatachalam et al. (2017) 423.5 178.4 15 326 106.1 10 0.6% 97.50 [-14.19, 209.19] Pilemann-Lyberg et al. (2018) 330 133.3 229 280 81.5 277 20.3% 50.00 [30.25, 69.75] Chen et al. (2020) 421.5 112.4 162 397.4 90.9 184 16.8% 24.10 [2.37, 45.83] Xia et al. (2020) 358 108 135 335 106 582 19.5% 23.00 [2.85, 43.15] Wakasugi et al. (2021) 333.9 78.1 39 331.4 79.2 183 10.8% 2.50 [-24.56, 29.56] Zhao et al. (2021) 372.1 142.1 104 325.4 96.2 239 8.9% 46.70 [16.79, 76.61] Heterogeneity: Chi ² = 12.42, df = 7 (P = 0.09); l ² = 44% -100.0% 28.68 [19.78, 37.58] -100 -50	Study or Subgroup	Mear	n SE	Tota				l Weid				
Navin et al. (2013) 276 33.3 13 257 19.6 21 19.9% 19.00 [-0.95, 38.95] Venkatachalam et al. (2017) 423.5 178.4 15 326 106.1 10 0.6% 97.50 [-14.19, 209.19] Pilemann-Lyberg et al. (2018) 330 133.3 229 280 81.5 277 20.3% 50.00 [30.25, 69.75] Chen et al. (2020) 421.5 112.4 162 397.4 90.9 184 16.8% 24.10 [2.37, 45.83] Xia et al. (2020) 358 108 135 335 106 582 19.5% 23.00 [2.85, 43.15] Wakasugi et al. (2021) 333.9 78.1 39 331.4 79.2 183 10.8% 2.50 [-24.56, 29.56] Zhao et al. (2021) 372.1 142.1 104 325.4 96.2 239 8.9% 46.70 [16.79, 76.61] Heterogeneity: Chi ² = 12.42, df = 7 (P = 0.09); l ² = 44% 725 1555 100.0% 28.68 [19.78, 37.58] -100 -50 0 50 100												
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	· · · · · · · · · · · · · · · · · · ·											_
Pilemann-Lyberg et al. (2018) 330 133.3 229 280 81.5 277 20.3% 50.00 [30.25, 69.75] Chen et al. (2020) 421.5 112.4 162 397.4 90.9 184 16.8% 24.10 [2.37, 45.83] Xia et al. (2020) 358 108 135 335 106 582 19.5% 23.00 [2.85, 43.15] Wakasugi et al. (2021) 333.9 78.1 39 331.4 79.2 183 10.8% 2.50 [-24.56, 29.56] Zhao et al. (2021) 372.1 142.1 104 325.4 96.2 239 8.9% 46.70 [16.79, 76.61] Total (95% Cl) 725 1555 100.0% 28.68 [19.78, 37.58] Heterogeneity: Chi ² = 12.42, df = 7 (P = 0.09); l ² = 44% Totat or coverall officet 7 = 6 31 (P < 0.0001)												
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$									· · · · · · · · · · · · · · · · · · ·			
Xia et al. (2020) 358 108 135 335 106 582 19.5% 23.00 [2.85, 43.15] Wakasugi et al. (2021) 333.9 78.1 39 331.4 79.2 183 10.8% 2.50 [-24.56, 29.56] Zhao et al. (2021) 372.1 142.1 104 325.4 96.2 239 8.9% 46.70 [16.79, 76.61] Total (95% Cl) 725 1555 100.0% 28.68 [19.78, 37.58] -100 -50 0 50 100 												_
Wakasugi et al. (2021) 333.9 78.1 39 331.4 79.2 183 10.8% 2.50 [-24.56, 29.56] Zhao et al. (2021) 372.1 142.1 104 325.4 96.2 239 8.9% 46.70 [16.79, 76.61] Total (95% Cl) 725 1555 100.0% 28.68 [19.78, 37.58] Heterogeneity: Chi ² = 12.42, df = 7 (P = 0.09); l ² = 44% Totat for overall officit 7 = 6.31 (P < 0.0001)										-		
Zhao et al.(2021) 372.1 142.1 104 325.4 96.2 239 8.9% 46.70 [16.79, 76.61] Total (95% Cl) 725 1555 100.0% 28.68 [19.78, 37.58] Heterogeneity: Chi ² = 12.42, df = 7 (P = 0.09); l ² = 44% Totat for overall effect: 7 = 6.31 (P < 0.0001)	. ,											
Total (95% Cl) 725 1555 100.0% 28.68 [19.78, 37.58] Heterogeneity: Chi ² = 12.42, df = 7 (P = 0.09); l ² = 44% $-100 - 50 0 50 100$											_	
Heterogeneity: $Chi^2 = 12.42$, df = 7 (P = 0.09); $l^2 = 44\%$ Test for everall effect $Z = 6.31$ (P < 0.00001)	Zhao et al.(2021)	372.	142.1	104	325.4	4 96.	2 235	9 8.5	46.70 [16.79, 7	6.61]		
Test for every leftert $Z = 6.31 (P < 0.00001)$ $-100 -50 0 50 100$	Total (95% CI)			725			1555	5 100.0	0% 28.68 [19.78, 3	7.58]		•
Tost for overall effect: $7 = 6.31 (P < 0.00001)$	Hotorogonoity: Chi ² = 12.42	lf = 7 (P	= 0.09)	l² = 44	%					-	100 50 0	F0 400
tavours low UA tavours high UA	neleiugeneily. Oni – 12.42, C	1 (P < 0	00001)									
		1 (1 . 0.										

the controls. For different phases of DR, UA levels increased significantly in participants with PDR than those in the controls with diabetes. No significant difference was found in patients with NPDR (WMD = 22.50; 95% CI: -6.07, 51.08; P = 0.120; $I^2 = 97\%$; P < 0.001), while the existing heterogeneity possibly influenced the robustness of this result. In the comparison between patients with NPDR and controls, we noted that the study conducted by Xia et al. (34) used different specimens and detection methods for UA measurement. When this sensitive study was removed, the heterogeneity among the studies decreased sharply, and the difference was statistically significant (WMD = 13.50; 95% CI: 3.12, 23.89; P = 0.010; $I^2 = 65\%$; P= 0.003). In addition, increased UA levels existed in patients with PDR compared with patients with NPDR in our study, with no significant heterogeneity. This finding is consistent with previous studies showing that participants with higher UA levels

retinopathy; NPDR, non-proliferative diabetic retinopathy.

have an increased risk of DR severity (from NPDR to PDR) (40, 51). Furthermore, a linear dose-response correlation of the elevation in patients with DR with different UA levels revealed a gradual increase from insignificant to significant. This is in line with the epidemiological survey showing that higher UA levels (\geq 378.00 µmol/L) were associated with a greater risk for DR (OR: 3.42; 95% CI: 1.64, 7.14; *P* = 0.001) (52), suggesting that elevated UA may be a potential risk factor for the progression of DR.

Increased UA is likely to play a role in the pathogenesis of DR. Accumulating experimental and clinical studies have found that oxidative stress and inflammatory responses induced by UA contribute to microvascular damage in DR (53, 54). Circulating UA is regarded as a powerful antioxidant that can remove superoxide and hydroxyl radicals in plasma, which may lead to an increase in reactive oxygen species production, which has been

TABLE 2 | Subgroup analysis of the studies for the UA levels and DR.

				Heterogeneity		
Subgroups	Number of studies	WMD (95% CI)	Р	l ²	Р	
Region						
Asia	16	24.67 (2.30; 47.03)	0.031	96.7%	< 0.00	
Others	5	76.30 (15.03; 137.57)	0.015	97.3%	< 0.00	
DR phase						
NPDR vs. DM without DR	10	22.50 (-6.07; 51.08)	0.120	97.0%	< 0.00	
PDR vs. DM without DR	8	46.57 (28.51; 64.63)	< 0.001	70.6%	0.001	
PDR vs. NPDR	8	28.68 (19.78; 37.58)	< 0.001	43.6%	0.088	
Diabetes types						
1	2	48.52 (39.02; 58.02)	< 0.001	0.0%	0.426	
2	14	27.16 (2.61; 51.71)	0.030	96.9%	< 0.00	
Both	5	60.51 (-19.27; 140.29)	0.137	97.9%	< 0.00	
Duration of diabetes, years						
≤15	10	36.52 (4.81; 68.23)	0.024	97.6%	< 0.00	
>15	6	62.22 (19.16; 105.27)	0.005	97.7%	< 0.00	
BMI, kg/m ²						
≤25	7	24.92 (8.14; 41.69)	0.004	89.5%	< 0.00	
>25	8	63.51 (13.11; 113.91)	0.014	98.4%	< 0.00	
FBG, mg/dL						
≤150	5	47.47 (-0.62; 95.56)	0.053	98.1%	< 0.00	
>150	7	52.76 (10.15; 95.37)	0.015	97.4%	< 0.00	
HbA _{1c} , %						
≤8.0	5	26.07 (2.62; 49.52)	0.029	90.4%	< 0.00	
>8.0	11	55.35 (23.92; 86.78)	0.001	97.4%	< 0.00	
LDL, mg/dL						
≤120	12	42.93 (13.78; 72.09)	0.004	97.9%	< 0.00	
>120	5	53.39 (37.11; 79.67)	<0.001	79.2%	0.001	
Specimen types						
Plasma	3	50.15 (-1.42, 101.72)	0.057	96.4%	< 0.00	
Serum	18	32.77 (13.99; 51.55)	0.001	94.9%	< 0.00	
UA level, μmol/L						
Quartile 1 (285.4–307.1)	5	3.72 (-32.87; 40.32)	0.842	95.3%	< 0.00	
Quartile 2 (307.1–333)	5	25.88 (4.87; 46.90)	0.016	88.3%	< 0.00	
Quartile 3 (333–378.15)	6	6.83 (0.09; 13.57)	0.047	0.0%	0.531	
Quartile 4 (378.15–505.6)	5	128.06 (72.37; 183.75)	0.001	96.8%	< 0.00	
NOS						
<7	10	42.26 (1.14; 83.38)	0.044	95.5%	< 0.00	
≥7	11	33.15 (7.45; 58.84)	0.011	97.6%	< 0.00	

DR, diabetic retinopathy; PDR, proliferative diabetic retinopathy; NPDR, non-proliferative diabetic retinopathy; NDR, non-diabetic retinopathy; BMI, body mass index; SD, standard deviation; NOS, Newcastle–Ottawa scale; HbA1c, glycated hemoglobin A1c; UA, Uric acid 1 mg/dL = 59.48 µmol/L; FBG, fasting blood glucose 1 mmol/L = 18.0 mg/dL; LDL, low-density lipoprotein 1 mmol/L = 38.66 mg/dL.

proven to cause coagulation disorders in the microcirculation (55). Furthermore, previous studies have demonstrated that UA could activate the NLRP3/NALP3 inflammasome and increase the expression of inflammatory factors such as TNF- α , IL-6, and CRP (17, 56). Several meta-analyses have shown higher levels of these inflammatory factors in patients with DR than those without DR (18, 57, 58). These inflammatory mediators have been shown to induce vessel dilation, retinal edema, platelet aggregation, and other pathological changes at the onset of DR (59, 60). Moreover, UA-lowering therapy has been

confirmed to significantly decrease retinal and plasma levels of inflammatory cytokines and adhesion factors in streptozotocininduced diabetes in rats (61). The role of anti-vascular endothelial growth factor (anti-VEGF) agents in targeting inflammation treatment to slow down the progression of DR has recently been regarded as effective (62). In addition, patients with diabetes with decreased urine UA excretion have been reported to have an increased risk of DR (63).

Since obvious heterogeneity existed among the 21 studies, it was imperative to explore the sources of heterogeneity.

Quartile 2 29.80 (1.26, 58.34) Longo-Mbenza et al.(2014) 0.00 (-36, 27, 36, 27) Zhang et al.(2018) 41.70 (29.09, 54.31) Melo et al.(2018) 45.80 (34.18, 57.42) Wakasugi et al.(2021) 3.60 (-7.55, 14.75) Subgroup, DL (1² = 88.3%, p = 0.000) 25.88 (4.87, 46.90) Quartile 3 6.00 (-11.25, 23.25) Weitzman et al.(1997) 6.00 (-0.86, 16.86) Yhaay at al.(2020) -2.30 (-27.44, 22.84) Xia et al.(2020) 9.70 (-14.89, 54.29) Nakayama et al.(2021) -12.00 (-37.30, 13.30) Zhao et al.(2021) -12.00 (-37.30, 13.30) Subgroup, DL (1² = 0.0%, p = 0.531) 9.50 (90.76, 108.24) Quartile 4 99.50 (90.76, 108.24) Yia et al.(2020) 98.40 (69.85, 126.95) Yenkatachalam et al.(2017) 99.20 (14.54, 183.86) Chen et al.(2020) 48.00 (29.56, 66.44) Subgroup, DL (1² = 96.4%, p = 0.000) 128.06 (72.37, 183.75) Heterogeneity between groups: p = 0.000 128.06 (72.37, 183.75)	IA level and Author,year	Effect (95% CI)	Weigh
Dukoga et al. (1991) Aavin et al. (2013) Cui et al. (2017) Pilemann-Lyberg et al (2018) Subgroup, DL (I ² = 95.3%, p = 0.000) Quartile 2 Cai et al. (2006) Congo-Mbenza et al. (2014) Chang et al. (2018) Vakasugi et al. (2018) Vakasugi et al. (2021) Subgroup, DL (I ² = 88.3%, p = 0.000) Quartile 3 Weitzman et al. (1997) fuang et al. (2020) Quartile 3 Weitzman et al. (2021) Subgroup, DL (I ² = 88.3%, p = 0.000) Quartile 4 Kia et al. (2021) Subgroup, DL (I ² = 0.0%, p = 0.531) Quartile 4 Kia et al. (2020) Subgroup, DL (I ² = 96.4%, p = 0.000) Heterogeneity between groups: p = 0.000	Quartile 1		
Navin et al. (2013) Cui et al. (2017) Pilemann-Lyberg et al. (2018) Subgroup, DL ($I^* = 95.3\%$, p = 0.000) Cuartile 2 Cai et al. (2006) Congo-Mbenza et al. (2014) Chang et al. (2018) Welo et al. (2019) Cuartile 3 Weitzman et al. (1997) Huang et al. (2020) Cuartile 3 Weitzman et al. (2021) Cuartile 3 Weitzman et al. (2021) Cuartile 4 Kia et al. (2021) Chang samar et al. (2014) Chuengsamarn et al. (2014) Chuengsamarn et al. (2017) Chang et al. (2021) Cuartile 4 Kia et al. (2020) Subgroup, DL ($I^* = 96.4\%$, p = 0.000) Heterogeneity between groups: p = 0.000	'anko et al.(1983) 🛨 💾	-35.40 (-56.24, -14.56)	4.9
Lui et al. (2017) -26.10 (-39.29, -12.91) Pilemann-Lyberg et al. (2018) 54.00 (37.50, 70.50) Subgroup, DL ($1^2 = 95.3\%$, p = 0.000) 3.72 (-32.87, 40.32) 2 Quartile 2 29.80 (1.26, 58.34) 0.00 (-36.27, 36.27) Chang et al. (2018) 41.70 (29.09, 54.31) 0.00 (-36.27, 36.27) Makasugi et al. (2018) 41.70 (29.09, 54.31) 45.80 (34.18, 57.42) Vakasugi et al. (2021) 3.60 (-7.55, 14.75) 52.88 (4.87, 46.90) 2 Quartile 3 Weitzman et al. (1997) 6.00 (-11.25, 23.25) -2.30 (-27.44, 22.84) Kia et al. (2020) 8.00 (-0.86, 16.86) 29.50 (90.76, 108.24) -12.00 (-37.30, 13.30) Chautral et al. (2021) -12.00 (-37.30, 13.30) 17.80 (-5.06, 40.66) 6.83 (0.09, 13.57) 2 Quartile 4 99.50 (90.76, 108.24) 99.50 (90.76, 108.24) 99.20 (14.54, 183.86) 48.00 (29.56, 66.44) Quartile 4 40 (69.85, 126.95) 99.20 (14.54, 183.86) 48.00 (29.56, 66.44) 303.40 (259.15, 347.65) 128.06 (72.37, 183.75) 2 Quartile 4 48.00 (29.26, 66.44) 303.40 (259.15, 347.65) 128.06 (72.37, 183.75) 2 Quartile 4 48.000 (29.56, 66.44) 303.4	Dlukoga et al.(1991)	-10.00 (-42.93, 22.93)	4.5
Wilemann-Lyberg et al. (2018) 54.00 $(37.50, 70.50)$ Subgroup, DL (I ² = 95.3%, p = 0.000) $3.72 (-32.87, 40.32)$ 2 Duartile 2 2ai et al. (2016) $29.80 (1.26, 58.34)$ $0.00 (-36.27, 36.27)$ Change et al. (2018) 41.70 (29.09, 54.31) $45.80 (34.18, 57.42)$ $3.60 (-7.55, 14.75)$ Subgroup, DL (I ² = 88.3%, p = 0.000) $3.60 (-7.55, 14.75)$ $3.60 (-7.55, 14.75)$ $25.88 (4.87, 46.90)$ 2 Quartile 3 Veitzman et al. (2020) $3.60 (-7.55, 14.75)$ $2.30 (-27.44, 22.84)$ $8.00 (-36.6, 16.86)$ Quartile 3 Veitzman et al. (2020) $8.00 (-3.65, 16.86)$ $-3.30 (-27.44, 22.84)$ Gia et al. (2020) $8.00 (-3.65, 16.86)$ $-3.30 (-27.44, 22.84)$ $8.00 (-3.65, 16.86)$ Veitzman et al. (2020) $-3.0 (-27.44, 22.84)$ $-12.00 (-37.30, 13.30)$ $-12.00 (-37.30, 13.30)$ thao et al. (2021) $-12.00 (-37.30, 13.30)$ $-12.00 (-37.30, 13.30)$ $-12.00 (-37.30, 13.30)$ thao et al. (2014) 99.50 (90.76, 108.24) $99.50 (90.76, 108.24)$ $99.50 (90.76, 108.24)$ Vuartile 4 $99.50 (90.76, 108.24)$ $99.20 (14.54, 183.86)$ $48.00 (29.56, 66.44)$ Subgroup, DL (I ² = 96.4%, p = 0.000) $48.00 (29.5$	lavin et al.(2013)	33.90 (18.88, 48.92)	5.0
hubgroup, DL (I ² = 95.3%, p = 0.000) 3.72 (-32.87, 40.32) 2 hubgroup, DL (I ² = 95.3%, p = 0.000) 3.72 (-32.87, 40.32) 2 hang et al. (2016) 29.80 (1.26, 58.34) 0.00 (-36.27, 36.27) hang et al. (2018) 45.80 (34.18, 57.42) 3.60 (-7.55, 14.75) Vakasugi et al. (2021) 3.60 (-7.55, 14.75) 3.60 (-7.55, 14.75) hubgroup, DL (I ² = 88.3%, p = 0.000) 25.88 (4.87, 46.90) 2 huartile 3 6.00 (-11.25, 23.25) 3.60 (-7.55, 14.75) huartile 3 6.00 (-27.44, 22.84) 8.00 (-0.86, 16.86) har et al. (2020) 9.70 (-14.89, 54.29) -2.30 (-27.44, 22.84) has et al. (2021) -2.30 (-27.6, 108.24) -2.30 (-3.73, 0, 13.30) has et al. (2021) -12.00 (-37.30, 13.30) 17.80 (-5.06, 40.66) habgroup, DL (I ² = 0.0%, p = 0.531) 99.50 (90.76, 108.24) 99.50 (90.76, 108.24) haver et al. (2014) 99.50 (90.76, 108.24) 99.50 (90.76, 108.24) 99.20 (14.54, 183.86) haver et al. (2020) 48.00 (29.56, 66.44) 303.40 (259.15, 347.65) 128.06 (72.37, 183.75) 2 haver et al. (2020) 48.00 (29.56, 66.44) 128.06 (72.37, 183.75) 2 haver et al.	Cui et al.(2017) 🔹	-26.10 (-39.29, -12.91)	5.0
huartile 2 29.80 (1.26, 58.34) ongo-Mbenza et al. (2014) 0.00 (-36.27, 36.27) hang et al. (2018) 41.70 (29.09, 54.31) telo et al. (2018) 45.80 (34.18, 57.42) Vakasugi et al. (2021) 3.60 (-7.55, 14.75) tuartile 3 6.00 (-11.25, 23.25) Veitzman et al. (2020) -2.30 (-27.44, 22.84) ia et al. (2020) 8.00 (-0.86, 16.86) tai et al. (2021) -12.00 (-37.30, 13.30) hao et al. (2021) -12.00 (-37.30, 13.30) hao et al. (2021) -12.00 (-37.62, 7, 18.375) huartile 4 99.50 (90.76, 108.24) ia et al. (2020) 99.20 (14.54, 183.86) Huartile 4 99.50 (90.76, 108.24) ia et al. (2020) 99.20 (14.54, 183.86) ten et al. (2020) 99.20 (14.54, 183.75) hawki et al. (2020) 128.06 (72.37, 183.75) hawki et al. (2020) 128.06 (72.37, 183.75) hawki et al. (2020) 128.06 (72.37, 183.75	ilemann-Lyberg et al.(2018)	► 54.00 (37.50, 70.50)	5.0
ai et al. (2006) 29.80 (1.26, 58.34) ongo-Mbenza et al. (2014) 0.00 (-36.27, 36.27) hang et al. (2018) 41.70 (29.09, 54.31) lelo et al. (2018) 45.80 (34.18, 57.42) /akasugi et al. (2021) 3.60 (-7.55, 14.75) ubgroup, DL (l ⁷ = 88.3%, p = 0.000) 25.88 (4.87, 46.90) 2 /uartile 3 6.00 (-11.25, 23.25) -2.30 (-27.44, 22.84) ia et al. (2020) 8.00 (-0.86, 16.86) 19.70 (-14.89, 54.29) akayama et al. (2021) -12.00 (-37.30, 13.30) 17.80 (-5.06, 40.66) ubgroup, DL (l ⁷ = 0.0%, p = 0.531) 6.83 (0.09, 13.57) 2 uartile 4 ia et al. (2020) 48.00 (29.56, 66.44) 99.20 (14.54, 183.86) hen et al. (2020) 48.00 (29.56, 66.44) 99.20 (14.54, 183.86) 48.00 (29.55, 547.65) ubgroup, DL (l ⁷ = 96.4%, p = 0.000) 128.06 (72.37, 183.75) 2	ubgroup, DL (1 ² = 95.3%, p = 0.000)	3.72 (-32.87, 40.32)	24.6
ongo-Mbenza et al.(2014) 0.00 (-36.27, 36.27) hang et al.(2018) 41.70 (29.09, 54.31) lelo et al.(2018) 45.80 (34.18, 57.42) /akasugi et al.(2021) 3.60 (-7.55, 14.75) ubgroup, DL (I ² = 88.3%, p = 0.000) 25.88 (4.87, 46.90) 2 /uartile 3 6.00 (-11.25, 23.25) -2.30 (-27.44, 22.84) /akayama et al.(2020) 8.00 (-0.86, 16.86) 19.70 (-14.89, 54.29) /akayama et al.(2021) 17.80 (-5.06, 40.66) 19.70 (-14.89, 54.29) /akayama et al.(2021) -12.00 (-37.30, 13.30) 17.80 (-5.06, 40.66) /akayama et al.(2014) 99.50 (90.76, 108.24) 99.50 (90.76, 108.24) /akatachalam et al.(2017) 99.20 (14.54, 183.86) 48.00 (29.56, 66.44) /akay et al.(2020) 303.40 (259.15, 347.65) 128.06 (72.37, 183.75) 2 /akayama et al.(2020) 303.40 (259.15, 347.65) 128.06 (72.37, 183.75) 2	luartile 2		
hang et al. (2018) lelo et al. (2018) /akasugi et al. (2021) ubgroup, DL (l ⁷ = 88.3%, p = 0.000) uartile 3 /eitzman et al. (1997) uang et al. (2020) akur et al. (2020) akur et al. (2020) akuyama et al. (2021) ubgroup, DL (l ⁷ = 0.0%, p = 0.531) uartile 4 ia et al. (2014) huengsamarn et al. (2014) hen et al. (2020) hawki et al. (2020) uartile 4 ia et al. (2014) huengsamarn et al. (2017) hen et al. (2020) hawki et al. (2020) eterogeneity between groups: p = 0.000	ai et al.(2006)	- 29.80 (1.26, 58.34)	4.7
elo et al. (2018) 45.80 (34.18, 57.42) /akasugi et al. (2021) 3.60 (-7.55, 14.75) ubgroup, DL (I ² = 88.3%, p = 0.000) 25.88 (4.87, 46.90) 2 uartile 3 6.00 (-11.25, 23.25) -2.30 (-27.44, 22.84) /a et al. (2020) 8.00 (-0.86, 16.86) 19.70 (-14.89, 54.29) akir et al. (2021) -12.00 (-37.30, 13.30) 17.80 (-5.06, 40.66) /abgroup, DL (I ² = 0.0%, p = 0.531) 6.83 (0.09, 13.57) 2 uartile 4 99.50 (90.76, 108.24) 99.20 (14.54, 183.86) at al. (2014) 99.20 (14.54, 183.86) 48.00 (29.56, 66.44) hem et al. (2020) 48.00 (29.56, 66.44) 303.40 (259.15, 347.65) 128.06 (72.37, 183.75) 2 eterogeneity between groups: p = 0.000 128.06 (72.37, 183.75) 2	ongo-Mbenza et al.(2014)	0.00 (-36.27, 36.27)	4.4
akasugi et al. (2021) 3.60 (-7.55, 14.75) ubgroup, DL (l ² = 88.3%, p = 0.000) 25.88 (4.87, 46.90) 2 uartile 3 6.00 (-11.25, 23.25) -2.30 (-27.44, 22.84) a et al. (2020) 8.00 (-0.86, 16.86) 19.70 (-14.89, 54.29) akir et al. (2021) 19.70 (-14.89, 54.29) -12.00 (-37.30, 13.30) nao et al. (2021) 17.80 (-5.06, 40.66) 6.83 (0.09, 13.57) uartile 4 a et al. (2014) 99.50 (90.76, 108.24) huengsamarn et al. (2017) 98.40 (69.85, 126.95) 99.20 (14.54, 183.86) hawki et al. (2020) 48.00 (29.56, 66.44) 303.40 (259.15, 347.65) ubgroup, DL (l ² = 96.4%, p = 0.000) 128.06 (72.37, 183.75) 2	nang et al.(2018)	41.70 (29.09, 54.31)	5.0
ubgroup, DL (l ² = 88.3%, p = 0.000) 25.88 (4.87, 46.90) 2 uartile 3 (eitzman et al.(1997) 6.00 (-11.25, 23.25) -2.30 (-27.44, 22.84) uang et al.(2020) 8.00 (-0.86, 16.86) 19.70 (-14.89, 54.29) -12.00 (-37.30, 13.30) akir et al.(2021) 17.80 (-5.06, 40.66) -12.00 (-37.30, 13.30) 17.80 (-5.06, 40.66) uartile 4 6.83 (0.09, 13.57) 2 uartile 4 99.50 (90.76, 108.24) 98.40 (69.85, 126.95) nakatachalam et al.(2014) 99.50 (90.76, 108.24) huengsamarn et al.(2017) 99.20 (14.54, 183.86) hawki et al.(2020) 48.00 (29.56, 66.44) ubgroup, DL (l ² = 96.4%, p = 0.000) 128.06 (72.37, 183.75) 2	elo et al.(2018)	45.80 (34.18, 57.42)	5.1
uartile 3 6.00 (-11.25, 23.25) uarget al.(2005) -2.30 (-27.44, 22.84) ia et al.(2020) $8.00 (-0.86, 16.86)$ akyama et al.(2021) 19.70 (-14.89, 54.29) hao et al.(2021) -12.00 (-37.30, 13.30) ia et al.(2021) 6.83 (0.09, 13.57) uartile 4 6.83 (0.09, 13.57) ia et al.(2014) 99.50 (90.76, 108.24) huengsamarn et al.(2017) 99.20 (14.54, 183.86) hen et al.(2020) 48.00 (29.56, 66.44) awki et al.(2020) 303.40 (259.15, 347.65) ubgroup, DL (l ² = 96.4%, p = 0.000) 128.06 (72.37, 183.75)	/akasugi et al.(2021) 🔶	3.60 (-7.55, 14.75)	5.1
eitzman et al. (1997) $6.00 (-11.25, 23.25)$ uang et al. (2005) $-2.30 (-27.44, 22.84)$ a et al. (2020) $8.00 (-0.86, 16.86)$ akir et al. (2021) $19.70 (-14.89, 54.29)$ akayama et al. (2021) $-12.00 (-37.30, 13.30)$ nao et al. (2021) $17.80 (-5.06, 40.66)$ ubgroup, DL (l ² = 0.0%, p = 0.531) $6.83 (0.09, 13.57)$ uartile 4 99.50 (90.76, 108.24) a et al. (2014) 98.40 (69.85, 126.95) uartile 4 99.20 (14.54, 183.86) a et al. (2020) $48.00 (29.56, 66.44)$ solution of the et al. (2020) $303.40 (259.15, 347.65)$ ubgroup, DL (l ² = 96.4%, p = 0.000) $128.06 (72.37, 183.75)$	ubgroup, DL (l ² = 88.3%, p = 0.000)	25.88 (4.87, 46.90)	24.4
uang et al. (2005) -2.30 (-27.44, 22.84) ia et al. (2020) 8.00 (-0.86, 16.86) akir et al. (2020) 19.70 (-14.89, 54.29) akayama et al. (2021) -12.00 (-37.30, 13.30) hao et al. (2021) 17.80 (-5.06, 40.66) ubgroup, DL (1^2 = 0.0%, p = 0.531) 6.83 (0.09, 13.57) uartile 4 99.50 (90.76, 108.24) ia et al. (2014) 98.40 (69.85, 126.95) hen et al. (2020) 48.00 (29.56, 66.44) hawki et al. (2020) 303.40 (259.15, 347.65) ubgroup, DL (1^2 = 96.4%, p = 0.000) 128.06 (72.37, 183.75)	uartile 3		
ia et al. (2020) $8.00 (-0.86, 16.86)$ akir et al. (2020) $19.70 (-14.89, 54.29)$ akayama et al. (2021) $-12.00 (-37.30, 13.30)$ hao et al. (2021) $17.80 (-5.06, 40.66)$ ubgroup, DL (l ² = 0.0%, p = 0.531) $6.83 (0.09, 13.57)$ uartile 4 $99.50 (90.76, 108.24)$ ia et al. (2014) $98.40 (69.85, 126.95)$ hen et al. (2017) $99.20 (14.54, 183.86)$ hen et al. (2020) $48.00 (29.56, 66.44)$ ubgroup, DL (l ² = 96.4%, p = 0.000) $128.06 (72.37, 183.75)$	/eitzman et al.(1997) 😽 🚼	6.00 (-11.25, 23.25)	5.0
akir et al. (2020) $19.70(-14.89, 54.29)$ akayama et al. (2021) $-12.00(-37.30, 13.30)$ hao et al. (2021) $17.80(-5.06, 40.66)$ ubgroup, DL (I ² = 0.0%, p = 0.531) $6.83(0.09, 13.57)$ uartile 4 $99.50(90.76, 108.24)$ ia et al. (2014) $99.50(90.76, 108.24)$ huengsamarn et al. (2017) $99.20(14.54, 183.86)$ hen et al. (2020) $48.00(29.56, 66.44)$ ubgroup, DL (I ² = 96.4%, p = 0.000) $303.40(259.15, 347.65)$ eterogeneity between groups: p = 0.000 $128.06(72.37, 183.75)$	uang et al.(2005)	-2.30 (-27.44, 22.84)	4.8
akayama et al.(2021) -12.00 (-37.30, 13.30) hao et al.(2021) 17.80 (-5.06, 40.66) ubgroup, DL (l ² = 0.0%, p = 0.531) 6.83 (0.09, 13.57) uartile 4 99.50 (90.76, 108.24) ia et al.(2014) 98.40 (69.85, 126.95) huengsamarn et al.(2017) 99.20 (14.54, 183.86) hen et al.(2020) 48.00 (29.56, 66.44) hawki et al.(2020) 303.40 (259.15, 347.65) ubgroup, DL (l ² = 96.4%, p = 0.000) 128.06 (72.37, 183.75)	ia et al.(2020) 💽	8.00 (-0.86, 16.86)	5.1
hao et al. (2021) $ubgroup, DL (l^2 = 0.0\%, p = 0.531)$ uartile 4 a et al. (2014) huengsamarn et al. (2014) enkatachalam et al. (2017) hawki et al. (2020) $ubgroup, DL (l^2 = 96.4\%, p = 0.000)$ eterogeneity between groups: p = 0.000 17.80 (-5.06, 40.66) 6.83 (0.09, 13.57) 99.50 (90.76, 108.24) 98.40 (69.85, 126.95) 99.20 (14.54, 183.86) 48.00 (29.56, 66.44) 303.40 (259.15, 347.65) 128.06 (72.37, 183.75) 28.06 (72.37, 183.75)	akır et al.(2020)	- 19.70 (-14.89, 54.29)	4.5
ubgroup, DL (l ² = 0.0%, p = 0.531) 6.83 (0.09, 13.57) 2 uartile 4 99.50 (90.76, 108.24) ia et al.(2014) 98.40 (69.85, 126.95) huengsamarn et al.(2017) 99.20 (14.54, 183.86) hen et al.(2020) 48.00 (29.56, 66.44) hawki et al.(2020) 303.40 (259.15, 347.65) ubgroup, DL (l ² = 96.4%, p = 0.000) 128.06 (72.37, 183.75)	akayama et al.(2021) 🛛 😽	-12.00 (-37.30, 13.30)	4.8
uartile 4 ia et al.(2014) huengsamarn et al.(2014) enkatachalam et al.(2017) hen et al.(2020) hawki et al.(2020) ubgroup, DL (l ² = 96.4%, p = 0.000) eterogeneity between groups: p = 0.000	hao et al.(2021)	17.80 (-5.06, 40.66)	4.8
ia et al.(2014) 99.50 (90.76, 108.24) huengsamarn et al.(2014) 98.40 (69.85, 126.95) enkatachalam et al.(2017) 99.20 (14.54, 183.86) hen et al.(2020) 48.00 (29.56, 66.44) hawki et al.(2020) 303.40 (259.15, 347.65) ubgroup, DL (l ² = 96.4%, p = 0.000) 128.06 (72.37, 183.75) eterogeneity between groups: p = 0.000 128.06 (72.37, 183.75)	ubgroup, DL (l ² = 0.0%, p = 0.531)	6.83 (0.09, 13.57)	29.1
whuengsamarn et al. (2014) 98.40 (69.85, 126.95) enkatachalam et al. (2017) 99.20 (14.54, 183.86) hen et al. (2020) 48.00 (29.56, 66.44) hawki et al. (2020) 303.40 (259.15, 347.65) ubgroup, DL (I ² = 96.4%, p = 0.000) 128.06 (72.37, 183.75) leterogeneity between groups: p = 0.000 128.06 (72.37, 183.75)	luartile 4		
ienkatachalam et al. (2017) 99.20 (14.54, 183.86) ihen et al. (2020) 48.00 (29.56, 66.44) hawki et al. (2020) 303.40 (259.15, 347.65) ubgroup, DL (I ² = 96.4%, p = 0.000) 128.06 (72.37, 183.75) leterogeneity between groups: p = 0.000 128.06 (72.37, 183.75)	ia et al.(2014)	 99.50 (90.76, 108.24) 	5.1
hen et al.(2020) hawki et al.(2020) ubgroup, DL (l ² = 96.4%, p = 0.000) eterogeneity between groups: p = 0.000	huengsamarn et al.(2014)	98.40 (69.85, 126.95)	4.7
hawki et al.(2020) ubgroup, DL (l ² = 96.4%, p = 0.000) eterogeneity between groups: p = 0.000	enkatachalam et al.(2017)	99.20 (14.54, 183.86)	2.7
ubgroup, DL (l ² = 96.4%, p = 0.000) eterogeneity between groups: p = 0.000	hen et al.(2020)	48.00 (29.56, 66.44)	4.9
ubgroup, DL (l ² = 96.4%, p = 0.000) eterogeneity between groups: p = 0.000	hawki et al.(2020)	303.40 (259.15, 347.65)	4.1
		128.06 (72.37, 183.75)	21.7
	eterogeneity between groups: p = 0.000		
Iverall, DL (1 ² = 96.8%, p = 0.000) 36.28 (15.68, 56.89) 10	verall, DL (l ² = 96.8%, p = 0.000)	> 36.28 (15.68, 56.89)	100.0

FIGURE 4 | Forest plot of the subgroup analysis on the concentrations of UA in patients with DR compared with controls with diabetes. UA, uric acid; DR, diabetic retinopathy; Quartile 1 (285.4–307.1); Quartile 2 (307.1–333); Quartile 3 (333–378.15); Quartile 4 (378.15–505.6), μ mol/L.

In subgroup analyses, high heterogeneity still existed. When stratified by quality score, the results showed that the heterogeneity failed to decrease, and the pooled results for each subgroup were approached. Notably, in subgroup analyses based on participants' clinical characteristics, such as duration of diabetes, FBG, and HbA_{1c}, increased UA levels were observed in patients with DR with relatively poor health status. Further meta-regression analyses revealed that heterogeneity existed in the participants included in each study with different BMI and FBG levels. Considering the critical role of BMI and FBG levels in diabetes management (64, 65), it is rational to regard the severity of diabetes as the underlying source of heterogeneity. Possibly due to the differential therapies and health care services received by participants, diabetes severity was unevenly distributed across the included studies. For instance, unlike in developed regions, studies conducted in less-developed regions show higher UA levels (29, 41). Moreover, two sensitive studies (34, 41) were defined contributing more to the heterogeneity in sensitivity analysis.



Present meta-analysis had several limitations that may have affected the final conclusions. First, we failed to infer the causality of this association because of uncertainty about the temporal order. Evidence suggests that DR increases the risk of hyperuricemia in patients with diabetes (66). By summarizing the results of existing studies, we found that sex-related differences in this association remain unclear and deserve to be further elucidated. A previous cohort study reported an increased risk of newly developed DR in women [hazard ratio (HR): 2.17; 95% CI: 1.40, 3.37; P < 0.001] but not in men (HR: 1.08; 95% CI: 0.71, 1.66; P = 0.998) (19). However, Yanan Hu et al. investigated the association between UA and VTDR, showing that no sex-related difference was observed in the effect of UA on an increased risk of VTDR after adjustment (21). In addition, only a few studies have been conducted on patients with type 1 DM (20, 39, 67), which restricts the interpretation of results. Second, since the individual's continuous data, such as concentrations of UA, FBG, and BMI levels, were unavailable in each study, there were certain deviations for the subgroup analysis by transforming continuous variables into binary variables using the mean. Finally, the possibility of selection and unidentified confounding biases cannot be excluded. For example, the use of anti-hyperuricemic medications could be a potential confounder. A previous study showed that anti-hyperuricemic drugs are protective against retinal inflammation (61). However, most of the studies included in the meta-analysis did not control the use of antihyperuricemic medication; therefore, they possibly enrolled participants receiving UA-lowering therapy, which would limit the rigor of our results. In addition, similar to UA, homocysteine (Hcy) plays an important role in evoking oxidative stress (68), and Hcy levels are physiologically closely related to UA (69). Previous studies have also provided evidence that Hcy may also lead to endothelial injury in the retinal microvasculature at higher levels (70); this confounding factor needs to be recognized equally. Within these limitations, more prospective studies of high quality deserve launching to further confirm the association.

CONCLUSIONS

In conclusion, our study provides evidence that UA levels are higher in patients with DR than those in the controls, but this difference is not statistically significant in the early phases. UA might be a potential biomarker for identifying disease severity in patients with DR rather than predicting the onset of DR among patients with diabetes. However, more prospective and highquality clinical evidence is required to confirm these findings.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/**Supplementary Material**, further inquiries can be directed to the corresponding author/s.

AUTHOR CONTRIBUTIONS

YCG and HLX contributed to the conception and design of this study. YCG and SYL performed the critical

REFERENCES

- Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the international diabetes federation diabetes Atlas, 9(th) edition. *Diabetes Res Clin Pract.* (2019) 157:107843. doi: 10.1016/j.diabres.2019.107843
- Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. Lancet. (2010) 376:124–36. doi: 10.1016/S0140-6736(09)62124-3
- Fong DS, Aiello L, Gardner TW, King GL, Blankenship G, Cavallerano JD, et al. Retinopathy in diabetes. *Diabetes Care.* (2004) 27(Suppl. 1):S84– 7. doi: 10.2337/diacare.27.10.2540
- Yau JW, Rogers SL, Kawasaki R, Lamoureux EL, Kowalski JW, Bek T, et al. Global prevalence and major risk factors of diabetic retinopathy. *Diabetes Care*. (2012) 35:556–64. doi: 10.2337/dc11-1909
- Wang W, Lo ACY. Diabetic retinopathy: pathophysiology and treatments. Int J Mol Sci. (2018) 19:1816. doi: 10.3390/ijms19061816
- Lechner J, O'Leary OE, Stitt AW. The pathology associated with diabetic retinopathy. Vision Res. (2017) 139:7–14. doi: 10.1016/j.visres.2017.04.003
- Hernández C, Simó-Servat A, Bogdanov P, Simó R. Diabetic retinopathy: new therapeutic perspectives based on pathogenic mechanisms. J Endocrinol Invest. (2017) 40:925–35. doi: 10.1007/s40618-017-0648-4
- Stitt AW. AGEs and diabetic retinopathy. Invest Ophthalmol Visual Sci. (2010) 51:4867–74. doi: 10.1167/iovs.10-5881
- Kang Q, Yang C. Oxidative stress and diabetic retinopathy: molecular mechanisms, pathogenetic role and therapeutic implications. *Redox Biol.* (2020) 37:101799. doi: 10.1016/j.redox.2020.101799
- Semeraro F, Cancarini A, dell'Omo R, Rezzola S, Romano MR, Costagliola C. Diabetic retinopathy: vascular and inflammatory disease. J Diabetes Res. (2015) 2015:582060. doi: 10.1155/2015/582060
- Sheemar A, Soni D, Takkar B, Basu S, Venkatesh P. Inflammatory mediators in diabetic retinopathy: deriving clinicopathological correlations for potential targeted therapy. *Indian J Ophthalmol.* (2021) 69:3035– 49. doi: 10.4103/ijo.IJO_1326_21
- Forrester JV, Kuffova L, Delibegovic M. The role of inflammation in diabetic retinopathy. *Front Immunol.* (2020) 11:583687. doi: 10.3389/fimmu.2020.583687
- Bardin T, Richette P. Definition of hyperuricemia and gouty conditions. *Curr* Opin Rheumatol. (2014) 26:186–91. doi: 10.1097/BOR.00000000000028
- 14. Lv Q, Meng XF, He FF, Chen S, Su H, Xiong J, et al. High serum uric acid and increased risk of type 2 diabetes: a systemic review and meta-analysis of prospective cohort studies. *PLoS ONE.* (2013) 8:e56864. doi: 10.1371/journal.pone.0056864
- Wang J, Yu Y, Li X, Li D, Xu C, Yuan J, et al. Serum uric acid levels and decreased estimated glomerular filtration rate in patients with type 2 diabetes: a cohort study and meta-analysis. *Diabetes Metabol Res Rev.* (2018) 34:e3046. doi: 10.1002/dmrr.3046
- 16. Yu S, Chen Y, Hou X, Xu D, Che K, Li C, et al. Serum uric acid levels and diabetic peripheral neuropathy in type 2 diabetes: a

appraisal and data extraction. YCG was responsible for the subsequent analysis, interpretation of the data used in the systematic review, and meta-analysis. YCG drafted the manuscript. HLX and YCG revised it critically for important intellectual content. All authors have checked and approved this version to be submitted and finally published.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fpubh. 2022.906760/full#supplementary-material

systematic review and meta-analysis. *Mol Neurobiol.* (2016) 53:1045–51. doi: 10.1007/s12035-014-9075-0

- Lyngdoh T, Marques-Vidal P, Paccaud F, Preisig M, Waeber G, Bochud M, et al. Elevated serum uric acid is associated with high circulating inflammatory cytokines in the population-based Colaus study. *PLoS ONE*. (2011) 6:e19901. doi: 10.1371/journal.pone.0019901
- Yao Y, Li R, Du J, Long L, Li X, Luo N. Interleukin-6 and diabetic retinopathy: a systematic review and meta-analysis. *Current Eye Res.* (2019) 44:564– 74. doi: 10.1080/02713683.2019.1570274
- Kuwata H, Okamura S, Hayashino Y, Tsujii S, Ishii H. Serum uric acid levels are associated with increased risk of newly developed diabetic retinopathy among Japanese male patients with type 2 diabetes: A prospective cohort study (diabetes distress and care registry at Tenri [DDCRT 13]). *Diabetes Metab Res Rev.* (2017) 33:e2905. doi: 10.1002/dmrr.2905
- Melo LGN, Morales PH, Drummond KRG, Santos DC, Pizarro MH, Barros BSV, et al. Current epidemiology of diabetic retinopathy in patients with type 1 diabetes: a national multicenter study in Brazil. *BMC Public Health.* (2018) 18:989. doi: 10.1186/s12889-018-5859-x
- Hu Y, Chan Z, Li C, Shi Y, She X, Gu C, et al. Higher serum uric acid levels are associated with an increased risk of vision-threatening diabetic retinopathy in type 2 diabetes patients. *Invest Ophthalmol Visual Sci.* (2021) 62:23. doi: 10.1167/iovs.62.4.23
- 22. Xia Q, Zhang SH, Yang SM, Zhu XL, Su S, Hu AP, et al. Serum uric acid is independently associated with diabetic nephropathy but not diabetic retinopathy in patients with type 2 diabetes mellitus. *JCMA*. (2020) 83:350– 6. doi: 10.1097/JCMA.0000000000285
- Yanko L, Goldbourt U, Michaelson IC, Shapiro A, Yaari S. Prevalence and 15-year incidence of retinopathy and associated characteristics in middle-aged and elderly diabetic men. *Bri J Ophthalmol.* (1983) 67:759– 65. doi: 10.1136/bjo.67.11.759
- Segato T, Midena E, Grigoletto F, Zucchetto M, Fedele D, Piermarocchi S, et al. The epidemiology and prevalence of diabetic retinopathy in the Veneto region of north east Italy. Veneto Group for Diabetic Retinopathy. *Diabetic Med.* (1991) 8:S11–6. doi: 10.1111/j.1464-5491.1991.tb02149.x
- Hu Y, Li Q, Min R, Deng Y, Xu Y, Gao L. The association between serum uric acid and diabetic complications in patients with type 2 diabetes mellitus by gender: a cross-sectional study. *PeerJ.* (2021) 9:e10691. doi: 10.7717/peerj.10691
- Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *BMJ.* (2009) 339:b2535. doi: 10.1136/bmj.b2535
- Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. *Eur J Epidemiol.* (2010) 25:603–5. doi: 10.1007/s10654-010-9491-z
- Olukoga AO, Erasmus RT, Akinlade KS, Okesina AB, Alanamu AA, Abu EA. Plasma urate in diabetes: relationship to glycaemia, glucose disposal, microvascular complications and the variations following oral glucose. *Diabetes Res Clin Practice*. (1991) 14:99–105. doi: 10.1016/0168-8227(91)90115-T

- Weitzman S, Maislos M, Bodner-Fishman B, Rosen S. Association of diabetic retinopathy, ischemic heart disease, and albuminuria with diabetic treatment in type 2 diabetic patients. A population-based study. *Acta Diabetol.* (1997) 34:275–9. doi: 10.1007/s005920050088
- Huang EJ, Kuo WW, Chen YJ, Chen TH, Chang MH, Lu MC, et al. Homocysteine and other biochemical parameters in Type 2 diabetes mellitus with different diabetic duration or diabetic retinopathy. *Clin Chim Acta*. (2006) 366:293–8. doi: 10.1016/j.cca.2005.10.025
- Cai XL, Wang F, Ji LN. Risk factors of diabetic retinopathy in type 2 diabetic patients. *Chin Med J.* (2006) 119:822– 6. doi: 10.1097/00029330-200605020-00005
- Navin S, Krishnamurthy N, Ashakiran S, Dayanand CD. The association of hypomagnesaemia, high normal uricaemia and dyslipidaemia in the patients with diabetic retinopathy [Article]. J Clin Diagn Res. (2013) 7:1852– 4. doi: 10.7860/JCDR/2013/6106.3332
- 33. Longo-Mbenza B, Mvitu Muaka M, Masamba W, Muizila Kini L, Longo Phemba I, Kibokela Ndembe D, et al. Retinopathy in non diabetics, diabetic retinopathy and oxidative stress: a new phenotype in Central Africa? *Int J Ophthalmol.* (2014) 7:293–301. doi: 10.3980/j.issn.2222-3959.2014.02.18
- Xia J, Wang Z, Zhang F. Association between related purine metabolites and diabetic retinopathy in type 2 diabetic patients. *Int J Endocrinol.* (2014) 2014:651050. doi: 10.1155/2014/651050
- Chuengsamarn S, Rattanamongkolgul S, Jirawatnotai S. Association between serum uric acid level and microalbuminuria to chronic vascular complications in Thai patients with type 2 diabetes. J Diabetes Compl. (2014) 28:124– 9. doi: 10.1016/j.jdiacomp.2013.12.002
- 36. Venkatachalam R, Krishnamoorthy RK, Kaliaperumal R, Anitha D, Anebaracy V, Buvana B, et al. Association of serum uric acid and lipid profile in type 2 diabetic patients with and without diabetic retinopathy [Article]. Asian J Pharm Clin Res. (2017) 10:112–4. doi: 10.22159/ajpcr.2017.v10i6.17029
- Cui J, Ren JP, Chen DN, Xin Z, Yuan MX, Xu J, et al. Prevalence and associated factors of diabetic retinopathy in Beijing, China: a cross-sectional study. *BMJ Open*. (2017) 7:e015473. doi: 10.1136/bmjopen-2016-015473
- Zhang D, Zhang W, Jin S, Wang W, Guo D, Wang L. Elevated serum total bilirubin concentrations are negatively associated with diabetic retinopathy among the chinese northeastern population. *Int J Endocrinol.* (2018) 2018:6539385. doi: 10.1155/2018/6539385
- Pilemann-Lyberg S, Hansen TW, Persson F, Theilade S, Singh Ahluwalia T, Frystyk J, et al. Uric acid is not associated with diabetic nephropathy and other complications in type 1 diabetes. *Nephrol Dialysis Transpl.* (2019) 34:659–66. doi: 10.1093/ndt/gfy076
- Chen D, Sun X, Zhao X, Liu Y. Associations of serum uric acid and urinary albumin with the severity of diabetic retinopathy in individuals with type 2 diabetes. *BMC Ophthalmol.* (2020) 20:467. doi: 10.1186/s12886-020-01713-5
- Shawki HA, Elzehery R, Shahin M, Abo-Hashem EM, Youssef MM. Evaluation of some oxidative markers in diabetes and diabetic retinopathy. *Diabetol Int.* (2021) 12:108–17. doi: 10.1007/s13340-020-00450-w
- Çakir I, Arifoglu HB, Günay NE, Pangal E, Sahin D, Sert GA, Duru N. Monocyte to high-density lipoprotein ratio: a novel inflammation marker related to diabetic retinopathy [Article]. *Erciyes Med J.* (2020) 42:190– 4. doi: 10.14744/etd.2020.32549
- 43. Wakasugi S, Mita T, Katakami N, Okada Y, Yoshii H, Osonoi T, et al. Associations between continuous glucose monitoring-derived metrics and diabetic retinopathy and albuminuria in patients with type 2 diabetes. *BMJ Open Diabetes Res Care.* (2021) 9:e001923. doi: 10.1136/bmjdrc-2020-001923
- 44. Nakayama Y, Yamaguchi S, Shinzato Y, Okamoto S, Millman JF, Yamashiro K, et al. Retrospective exploratory analyses on gender differences in determinants for incidence and progression of diabetic retinopathy in Japanese patients with type 2 diabetes mellitus. *Endo J.* (2021) 68:655–69. doi: 10.1507/endocrj.EJ20-0630
- 45. Zhao X, Liu Y, Zhang W, Meng L, Lv B, Lv C, et al. Relationships between retinal vascular characteristics and renal function in patients with type 2 diabetes mellitus. *Transl Vision Sci Technol.* (2021) 10:20. doi: 10.1167/tvst.10.2.20
- 46. Chen B, Benedetti A. Quantifying heterogeneity in individual participant data meta-analysis with binary outcomes. Syst Rev. (2017) 6:243. doi: 10.1186/s13643-017-0630-4

- Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. (2003) 327:557–60. doi: 10.1136/bmj.327.7414.557
- DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. (1986) 7:177–88. doi: 10.1016/0197-2456(86)90046-2
- Hayashino Y, Noguchi Y, Fukui T. Systematic evaluation and comparison of statistical tests for publication bias. J Epidemiol. (2005) 15:235– 43. doi: 10.2188/jea.15.235
- Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. *Biometrics*. (1994) 50:1088–101. doi: 10.2307/2533446
- Lee JJ, Yang IH, Kuo HK, Chung MS, Chen YJ, Chen CH, et al. Serum uric acid concentration is associated with worsening in severity of diabetic retinopathy among type 2 diabetic patients in Taiwan–a 3-year prospective study. *Diabetes Res Clin Practice*. (2014) 106:366–72. doi: 10.1016/j.diabres.2014.07.027
- 52. Hou L, Shi Y, Wang S, Chen Q, Li Q, Zhao M, et al. Associations of serum uric acid level with diabetic retinopathy and albuminuria in patients with type 2 diabetes mellitus. *J Int Med Res.* (2020) 48:300060520963980. doi: 10.1177/0300060520963980
- Xiong Q, Liu J, Xu Y. Effects of uric acid on diabetes mellitus and its chronic complications. *Int J Endocrinol.* (2019) 2019:9691345. doi: 10.1155/2019/9691345
- Zhu DD, Wang YZ, Zou C, She XP, Zheng Z. The role of uric acid in the pathogenesis of diabetic retinopathy based on Notch pathway. *Biochem Biophys Res Commun.* (2018) 503:921–9. doi: 10.1016/j.bbrc.2018.06.097
- Mazzali M, Hughes J, Kim YG, Jefferson JA, Kang DH, Gordon KL, et al. Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. *Hypertension*. (2001) 38:1101–6. doi: 10.1161/hy1101.092839
- Martinon F, Pétrilli V, Mayor A, Tardivel A, Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. *Nature*. (2006) 440:237– 41. doi: 10.1038/nature04516
- Song J, Chen S, Liu X, Duan H, Kong J, Li Z. Relationship between C-reactive protein level and diabetic retinopathy: a systematic review and meta-analysis. *PLoS ONE*. (2015) 10:e0144406. doi: 10.1371/journal.pone.0144406
- Yao Y, Li R, Du J, Li X, Zhao L, Long L, et al. Tumor necrosis factor-α and diabetic retinopathy: review and meta-analysis. *Clin Chim Acta*. (2018) 485:210–7. doi: 10.1016/j.cca.2018.06.028
- Kinuthia UM, Wolf A, Langmann T. Microglia and inflammatory responses in diabetic retinopathy. *Front Immunol.* (2020) 11:564077. doi: 10.3389/fimmu.2020.564077
- Mugisho OO, Rupenthal ID, Squirrell DM, Bould SJ, Danesh-Meyer HV, Zhang J, et al. Intravitreal pro-inflammatory cytokines in non-obese diabetic mice: modelling signs of diabetic retinopathy. *PLoS ONE.* (2018) 13:e0202156. doi: 10.1371/journal.pone.0202156
- Thounaojam MC, Montemari A, Powell FL, Malla P, Gutsaeva DR, Bachettoni A, et al. Monosodium urate contributes to retinal inflammation and progression of diabetic retinopathy. *Diabetes*. (2019) 68:1014–25. doi: 10.2337/db18-0912
- Carroll RM, Bracha P, Miller CG, Brucker AJ. Management of diabetic retinopathy in the anti-vascular endothelial growth factor era. *Retina*. (2021) 41:461–3. doi: 10.1097/IAE.000000000003071
- 63. Li LX, Lu JX, Shuai HP, Xia HF, Zhang R, Wang JW, et al. Decreased urine uric acid excretion is associated with diabetic retinopathy but not with lower limb atherosclerosis in hospitalized patients with type 2 diabetes. *Atherosclerosis*. (2015) 242:13–8. doi: 10.1016/j.atherosclerosis.2015.06.051
- Campbell L, Rössner S. Management of obesity in patients with type 2 diabetes. *Diabetic Med.* (2001) 18:345– 54. doi: 10.1046/j.1464-5491.2001.00546.x
- Stumvoll M, Goldstein BJ, van Haeften TW. Type 2 diabetes: principles of pathogenesis and therapy. *Lancet.* (2005) 365:1333– 46. doi: 10.1016/S0140-6736(05)61032-X
- 66. Choukem SP, Mengue JA, Doualla MS, Donfack OT, Beyiha G, Luma HN. Hyperuricaemia in patients with type 2 diabetes in a tertiary healthcare centre in sub-Saharan Africa: prevalence and determinants. *Trop Doctor*. (2016) 46:216–21. doi: 10.1177/0049475515626030
- Bjornstad P, Maahs DM, Rivard CJ, Pyle L, Rewers M, Johnson RJ, et al. Serum uric acid predicts vascular complications in adults with type 1 diabetes: the coronary artery calcification in type 1 diabetes study. *Acta Diabetol.* (2014) 51:783–91. doi: 10.1007/s00592-014-0611-1

- Perna AF, Ingrosso D, De Santo NG. Homocysteine and oxidative stress. Amino Acids. (2003) 25:409–17. doi: 10.1007/s00726-003-0026-8
- 69. Shi Y, Wu Z, Wu J, Chen Z, Li P. Serum homocysteine level is positively correlated with serum uric acid level in U.S. Adolescents: a cross sectional study. *Front Nutr.* (2022) 9:818836. doi: 10.3389/fnut.2022.818836
- Omae T, Nagaoka T, Tanano I, Yoshida A. Homocysteine inhibition of endothelium-dependent nitric oxide-mediated dilation of porcine retinal arterioles via enhanced superoxide production. *Invest Ophthalmol Visual Sci.* (2013) 54:2288–95. doi: 10.1167/iovs.12-11082

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Guo, Liu and Xu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.